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ABSTRACT 
Anticoagulants are used for the prevention and treatment of arterial and venous 
thromboembolism. Such therapy is always associated with an increased risk of 
bleeding. Intracranial hemorrhage is the most serious form of anticoagulants-
related bleeding and caries a high mortality rate. Many treating physicians and 
patients are reluctant to restart anticoagulation after such an event. For patients 
with continued increased risk of cardioembolism, the decision of when to restart 
anticoagulation is challenging and few small, single-center studies and case 
reports are the only available source of information.  
Prothrombin complex concentrates (PCC) have been shown to rapidly correct 
the prolonged prothrombin time associated with vitamin K antagonist (VKA) 
therapy. The clinical efficacy of such treatment for controlling bleeding or 
preventing post-operative hemorrhage in patients treated with VKA is uncertain. 
Thromboembolism is a potential side effect of PCC and there are limited data on 
the risk of such complications.  
New direct oral anticoagulants are approved as alternatives for VKA. These 
agents lack antidote and the management and outcome of patients with major 
bleeding on these agents is uncertain. In this thesis different aspects of the 
management of anticoagulants-associated bleeding complications are studied and 
discussed.  
A cohort of 234 patients from Sweden and Canada with VKA-related 
intracranial hemorrhage was analyzed to establish the optimal time point for 
resumption of anticoagulation. Early resumption carries a high risk of recurrent 
bleeding, whereas the risk of thromboembolism increases with delayed start. 
According to the result of our study, the optimal timing of resuming 
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anticoagulation after VKA-associated intracranial hemorrhage seems to be 
between week 10 and 30 after the event.  
A subgroup of the above-mentioned cohort was combined with another cohort 
from the Netherlands. A total of 135 patients were investigated to assess the 
effect of PCC - compared to plasma - on survival after VKA-related intracerebral 
hemorrhage. Unadjusted analysis showed a benefit for PCC treatment in 
reducing the 30-day all-cause mortality. After adjustment for differences in 
prognostic factors between the two treatment groups, especially the volume of 
intracerebral hematoma, the beneficial effect of PCC was attenuated and became 
non-significant. 
The safety of reversal of VKA with PCC was assessed in a third cohort of 160 
Swedish patients with a major bleeding event or before emergency surgery. Six 
patients (3.8%) developed thromboembolic events (5 arterial and 1 venous) 
within a week after the administration of PCC. In these patients, the unmasking 
of the increased risk for thromboembolism by the reversal of anticoagulation and 
the activation of the coagulation system by the bleeding or surgery, seem to be 
important contributing factors, while PCC seem to increase the risk only 
minimally, if any.  
A cohort of 1121 patients with major bleeding on dabigatran or warfarin, derived 
from 5 phase III trials, was used to study the management and outcomes of these 
bleeding events in the absence of an antidote to dabigatran. The patients who 
suffered major bleeding on dabigatran were older, had more renal impairment 
and were more frequently treated with antiplatelet agents or non-steroidal anti-
inflammatory drugs compared to those on warfarin, yet the outcome of 
dabigatran bleeding was better as reflected by a shorter stay by 1 day in the 
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intensive care unit and lower 30-day all-cause mortality compared to the 
warfarin group.  
 
In summary, PCC seem to be safe for the treatment of VKA-associated bleeding, 
but their beneficial effect over plasma in case of intracerebral hemorrhage is 
questionable. The absence of a reversal agent for dabigatran does not seem to 
impact negatively on the outcome after major bleeding. When intracranial 
hemorrhage occurs on VKA resumption of anticoagulation should be delayed for 
10-30 weeks.  
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POPULÄRVETENSKAPLIG SAMMANFATTNING 
 
Antikoagulantia, även kallade blodförtunnande, används för att förebygga och 
behandla en rad olika tillstånd som innebär en ökad risk för blodproppsbildning i 
artär- eller vensida. Användning av dessa medel innebär en ökad risk för 
allvarliga blödningar. Intrakraniell blödning (hjärnblödning) är den allvarligaste 
varianten av dessa blödningar och medför en hög dödlighet. Många behandlande 
läkare och patienter är tveksamma till att sätta in blodförtunnande igen efter en 
sådan händelse, men för patienter med fortsatt ökad risk för blodproppsbildning, 
måste blodförtunning återinsättas vid någon tidpunkt efter blödningen. Enstaka 
små studier och fallbeskrivningar är den enda informationskälla som finns 
tillgänglig som stöd för beslut om återinsättning av dessa läkemedel. 
Vid behov av snabbt upphävande av warfarineffekten har ett läkemedel, 
protrombinkomplexkoncentrat, visat sig kunna snabbt korrigera 
blodprovavvikelser orsakade av warfarinbehandling, men den kliniska effekten 
av sådan reversering för att stoppa blödningen eller förhindra en sådan efter 
operation på warfarinbehandlade patienter är inte studerad. Behandling med 
protrombinkomplexkoncentrat kan teoretiskt leda till en ökad risk för 
blodproppsbildning, och det finns några rapporter och små studier om sådana 
komplikationer efter behandling med dessa medel. 
Några av de nya blodförtunnandemedlen är registrerade som alternativ till 
warfarin. Till skillnad från warfarin saknar dessa mediciner modemedel som kan 
upphäva deras effekt och prognosen för patienter med större blödningar på dessa 
medel är fortfarande okänd.  
Denna avhandling berör olika aspekter av hantering av blödningskomplikationer 
av blodförtunnande läkemedel. 
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Studie I 
 
I denna studie analyserades 234 patienter från Sverige och Kanada med warfarin 
orsakad hjärnblödning för att fastställa den optimala tidpunkten för återinsättning 
av warfarin. Att sätta in warfarin tidigt efter en blödning innebär en hög risk för 
en ny blödning, medan att vänta lång tid med warfarin ökar risken för 
blodproppsbildning. I vår studie har vi noterat att den optimala tidpunkten för att 
återinsätta warfarin efter hjärnblödning förefaller vara mellan 10 och 30 veckor 
efter blödningen. 
Studie II 
 
I denna studie har vi analyserat data från totalt 135 patienter från Sverige, 
Kanada och Holland, som har drabbats av en speciell variant av hjärnblödning, 
intracerebral blödning, under warfarinbehandling. Vid en sådan blödning kan 
man ge antingen protrombinkomplexkoncentrat eller plasma för att upphäva 
warfarin effekten. Data analyserades för att bedöma effekten av 
protrombinkomplexkoncentrat jämfört med plasma för att förbättra 
överlevnaden. Den initiala analysen visade en fördel för behandling med 
protrombinkomplexkoncentrat med minskning av dödligheten under de första 30 
dagarna efter blödningen. Korrigering för skillnader mellan de två 
behandlingsgrupperna, framförallt volymen av hjärnblödningen, försvagade den 
gynnsamma effekten av protrombinkomplexkoncentrat. 
Protrombinkomplexkoncentrat verkar således inte minskar 30-dagars dödlighet 
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jämfört med plasma behandling för patienter med warfarinrelaterad intracerebral 
blödning. 
 
Studie III 
Säkerheten av behandling med protrombinkomplexkoncentrat utvärderades i en 
tredje grupp av 160 patienter i Sverige som fick detta läkemedel för att upphäva 
warfarineffekten på grund av en större blödningar eller före akut operation. 
Totalt drabbades 6 patienter av blodproppar (5 på artärsidan och 1 på vensidan) 
inom en vecka efter behandling med protrombinkomplexkoncentrat. Sådana 
patienter har redan en ökad risk för blodproppsbildning utan blodförtunnande 
läkemedel, och dessutom bidrar aktivering av koagulationssystemet pga. 
blödningen eller operationen till den ökade risken. Behandling med 
protrombinkomplexkoncentrat tycks öka risken för blodproppar endast minimalt. 
 
Studie IV 
En stor grupp av 1121 patienter med allvarliga blödningar på ett nytt 
blodförtunnande läkemedel (dabigatran) eller warfarin studerades för att bedöma 
utfallet av dessa blödningar i frånvaro av ett motmedel mot dabigatran. De 
patienter som drabbats av större blödningar på dabigatran var äldre, hade sämre 
njurfunktion och var oftare behandlade med andra mediciner som påverkar 
blodets levringsförmåga jämfört med warfaringruppen. Prognosen av blödningar 
på dabigatran var bättre i form av kortare vistelse på intensivvården samt lägre 
30-dagars dödlighet jämfört med warfaringruppen. 
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Sammanfattningsvis verkar protrombinkomplexkoncentrat vara säkert för 
behandling av warfarin relaterade blödningar, men deras fördel över plasma vid 
intracerebral blödning kan ifrågasättas. Frånvaron av ett motmedel för dabigatran 
verkar inte inverka negativt på utfallet av allvarliga blödningar. När en 
hjärnblödning inträffar hos en warfarin behandlad patient bör återinsättning av 
warfarin ske först efter 10-30 veckor. 
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1 INTRODUCTION 
Antithrombotic agents are used for the prevention and treatment of venous and 
arterial thromboembolism, which are important causes of morbidity and 
mortality. There are two classes of antithrombotic agents: antiplatelet agents and 
anticoagulants. Antiplatelet agents are most effective in preventing and treating 
arterial thromboembolism, where high sheer conditions lead to the development 
of thrombi rich in platelets and with only a small amount of fibrin.  
Anticoagulants, on the other hand, inhibit one or more factors in the coagulation 
cascade (Fig 1), leading to a reduction in fibrin formation, and are therefore most 
effective for venous thrombi, which are mainly composed of fibrin and red blood 
cells.  
 
ANTICOAGULANTS 
Anticoagulants are further divided according to the mode of administration into 
oral and parenteral agents. Parenteral anticoagulants can be either direct or 
indirect agents. The indirect parenteral anticoagulants include heparin, low 
molecular weight heparins (LMWH), fondaparinux and danaparoid. The effect 
of these agents is facilitated by endogenous plasma co-factors, the most 
important of which is antithrombin. Antithrombin inhibits the activity of several 
coagulation factors in the coagulation system, especially factor X and factor II. 
In the presence of LMWH, the inhibitory effect of antithrombin on factor X and 
II is greatly increased. The direct parenteral agents, on the other hand can 
directly inhibit coagulation factors without the need for other cofactors. Most of 
the available direct parenteral agents target, including hirudins, bivalirudin, and 
argatroban, inhibit thrombin. 
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Vitamin K antagonists have been the only available oral anticoagulants for over 
60 years. Recently, several oral agents have been developed that directly and 
selectively inhibit different factors in the coagulation system. This thesis focuses 
on the management of bleeding events complicating two different classes of oral 
anticoagulants: vitamin K antagonists and direct thrombin inhibitors.  
 
 
 
Figure.1 Site of action of the different anticoagulants 
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VITAMIN K ANTAGONISTS 
Vitamin K antagonists (VKA), also known as the coumarins, have been the only 
available oral anticoagulants for more than six decades. They were the mainstay 
for the prevention and treatment of arterial and venous thromboembolism. The 
efficacy of VKAs has been shown in several studies and for a wide range of 
indications1-3.  
Despite the long experience with VKAs and the wealth of evidence supporting 
their efficacy, they still have several drawbacks and many physicians still find 
them challenging to use4. First, there is considerable inter-patient dose response 
variability due to genetic and environmental factors5. Second, these agents have 
a narrow therapeutic window. Another factor is that VKAs exhibit a wide range 
of drug and diet interactions6. These factors combined necessitate regular 
laboratory monitoring and dose adjustment, which in turn is difficult to maintain 
with a good level of quality. 
 
Mechanism of action of VKA 
VKA act by inhibiting the C1 subunit of vitamin K epoxide reductase 
(VKORC1) enzyme complex. The enzyme is important for the cyclic conversion 
between vitamin K and the 2,3 vitamin K epoxide. This reduces the regeneration 
of vitamin K1 epoxide and results in a condition of an acquired vitamin K 
deficiency, which in turn interferes with the γ-carboxylation of glutamate 
residues (Gla) on the N-terminal regions of vitamin K-dependent proteins7-9. 
This γ-carboxylation is important for the procoagulant activity of vitamin K 
dependent factors (factor II, VII, IX, and X). The end result of treatment with 
VKA is the production of partially γ-carboxylated proteins with reduced 
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coagulant activity10,11. 
The same process results in the production of defective vitamin K dependent 
anticoagulant proteins C, S and Z. Reduction of the levels of these anticoagulant 
proteins is seen earlier than most pro-coagulant vitamin K dependent proteins 
due to the longer half-life of the latter (especially factor II). Treatment with 
VKAs is therefore potentially thrombogenic in the early treatment phase12, but 
the anticoagulant effect dominates later on.  
 
Monitoring VKAs anticoagulant activity 
Historically, the prothrombin time (PT) was used to monitor the intensity of 
anticoagulation during treatment with vitamin K antagonists. The PT, when 
measured with the Owren method commonly used in Scandinavian countries, is 
sensitive to the plasma levels of three vitamin K dependent coagulation factors 
(Factor II, VII and X), the functional level of which is reduced by VKAs. 
Prothrombin Time is either expressed in seconds, or as a ratio of the patient’s 
plasma value to that of plasma from a healthy control subject, or as a percentage 
of diluted normal plasma. The resulting PT is not standardized and is dependent 
on the responsiveness of the thromboplastin added in the test to the reduction of 
activatible vitamin K dependent factors and the type of instrument used, 
resulting in difficulties in comparing and monitoring the intensity of VKA 
anticoagulation when the test is performed by different laboratories or by using 
different reagents. The solution was to standardize the reporting of PT using an 
“International Sensitivity Index” (ISI) specific for each thromboplastin reagent, 
that reflects the responsiveness of the given thromboplastin to the reduction of 
activatible vitamin K-dependent coagulation factors compared with the primary 
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World Health Organization (WHO) international reference preparations13. The 
resulting International Normalized Ratio (INR) is calculated according to the 
following formula:  
INR = (patient PT/mean normal PT)ISI 
 
Optimal therapeutic intensity 
The goal of finding an optimal therapeutic intensity is to find a therapeutic 
window with maintained efficacy while causing the least side effect, the most 
important of which in case of anticoagulants is bleeding. Higher INR values are 
associated with an increased risk of bleeding14-16. The optimal therapeutic range 
may not be the same for all VKA indications. Depending on the underlying 
disease, characteristics of the patient and the balance between bleeding and 
thromboembolic risk, it may sometimes be necessary to adjust the INR target 
area upwards, thereby gaining efficacy while offering some safety, or vice versa. 
In venous thromboembolism, a “moderate-intensity” INR range of 2.0-3.0 was 
found to be as efficacious as a higher intensity one (3-0-4.0) while causing lower 
risk of bleeding17. Similarly, in patients with atrial fibrillation (AF), dose 
adjusted warfarin therapy to an INR of 2.0-3.0 is both effective and safe18-20. 
Conversely, lower intensity INR (<2.0) was found to be less effective than a 
moderate intensity INR regimen (2.0-3.0)21-26. The scenario is somewhat 
different in patients with prosthetic heart valves (PHV) and especially those with 
mitral mechanical heart prosthesis where experts (especially in Europe) 
recommend a higher intensity INR of up to 3.527,28. 
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THE NEW ANTICOAGULANTS 
During the past decade, several new agents have been discovered or molecularly 
engineered to either inhibit the initiation of coagulation by targeting the factor 
VIIa/tissue factor complex, or to inhibit the propagation of coagulation by 
blocking individual coagulation factors, like factor V, IX, or X, or by inhibiting 
the formation of fibrin by blocking the last enzymatic step in the coagulation 
cascade at the level of thrombin. Of these drugs, inhibitors of factor Xa and of 
thrombin are the two groups that have reached furthest in clinical trials and 
several agents in these groups are now registered worldwide. These new direct 
oral anticoagulants (DOACs) still have their own limitations and management of 
bleeding complications in the absence of a specific antidote has been a hot topic 
addressed by several recent publications. Very recently, the results from a pre-
clinical study on a humanized antibody that blocks the active form of FXII have 
shown promising antithrombotic effect without an increased bleeding risk29, but 
this dissociation remains to be demonstrated in the clinical setting. 
 
 
Oral thrombin inhibitors 
Thrombin has a central role in the coagulation system, and drugs targeting 
thrombin for their anticoagulant effect were the first to be developed. These 
drugs act by directly and reversibly blocking the active site of thrombin hence 
their name direct thrombin inhibitors (DTI). Several agents were developed in 
this group. The first, ximelagatran, showed promising results in phase III 
studies30 but was then withdrawn from the market in 2006 because of an 
increased risk of idiosyncratic hepatic toxicity31,32.  
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Dabigatran etexilate was the second oral DTI to be developed and tested in 
large-scale trials. After oral administration, it has a relatively low bioavailability 
of 6.5% with an inter-individual variability of CV≈30%33, reaching top plasma 
concentration after 1.5-3 hours. The prodrug is converted by unspecific 
ubiquitous esterases in the plasma to the active drug form, dabigatran, and is not 
dependent on cytochrome p450 for its metabolism 34. It is, however a substrate 
for the permeability-glycoprotein (P-gp) transporter system, which is responsible 
for the efflux of dabigatran into the intestinal tract, and drugs that induce or 
inhibit the P-gp system have the potential to interact with dabigatran. About 35% 
of circulating dabigatran is bound to plasma proteins34. The half-life of 
dabigatran is 14-17 hours in patients with normal renal function. Eighty percent 
of the active drug is eliminated unchanged through the renal route33. Because of 
this predominant renal elimination, the half-life of dabigatran is prolonged in 
patients with renal impairment and there is a risk of drug accumulation in these 
patients.  
 
Oral factor Xa inhibitors 
This group of anticoagulants includes a larger number of drugs than the thrombin 
inhibitors. Several of these agents (rivaroxaban, apixaban and edoxaban) are now 
licensed in different parts of the world for a number of indications. These agents 
are small molecules that bind directly and reversibly to the active form of factor 
X, thereby blocking the coagulation system at the confluence of the intrinsic and 
extrinsic pathways. These drugs have a higher bioavailability (rivaroxaban: 80%, 
apixaban: 60%, edoxaban: 50%), a similar time to peak plasma concentration 
(≈1-4 hours) a shorter half-life (≈6-14 hours), are more protein bound in the 
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circulation, and less dependent on renal excretion (apixaban: 25%, rivaroxaban: 
66%, edoxaban 35%) than dabigatran 35,36. 
 
TREATMENT INDICATIONS 
 
Atrial fibrillation 
Atrial fibrillation is the commonest cardiac arrhythmia. It is an independent risk 
factor for the development of cardiac thromboembolism and is associated with a 
fivefold increase in the risk of ischemic stroke without antithrombotic therapy 37, 
corresponding to annual rates of about 5%38. During an episode of atrial 
fibrillation, turbulent and slow blood flow in the atria, especially in the left atrial 
appendage, contributes to the increased risk of thrombus formation and 
subsequent embolization. The exact incidence of ischemic stroke in patients with 
AF varies widely depending on several other associated conditions, including 
age, sex, diabetes, hypertension, heart failure, previous ischemic neurological 
events and possibly arterial vascular disease in general 39,40.  
Several studies, including randomized controlled trials (RCT) have shown that 
treatment with VKAs reduces the risk of non-fatal ischemic stroke by two thirds. 
These agents were also shown to reduce the risk of fatal stroke by about 25%18-
20,38,41,42. Vitamin K antagonists have become the standard therapy for stroke 
prophylaxis in AF (SPAF) with increased risk of thromboembolism, but due to 
the limitations of VKAs and especially the fear of bleeding complications, the 
uptake of VKAs for this indication is still suboptimal. Large studies have shown 
that compared to warfarin, several of the DOACs (dabigatran 110mg43, 
rivaroxaban44, apixaban45 and edoxaban46) were non-inferior or even superior 
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(dabigatran 150mg)43 for the ischemic stroke prevention in patients with AF.  As 
with VKAs, treatment with these agents is associated with an increased risk of 
non-major and major bleeding events18-20,38,41-46 but the rates are somewhat lower 
for the DOACs than for warfarin43-46. 
.  
Venous thromboembolism 
Vitamin K antagonists have been shown to be effective for the treatment of deep 
venous thrombosis in the extremities as well as pulmonary embolism1. Results 
from the only one RCT that compared the use of anticoagulants to placebo in 
patients with pulmonary thromboembolism showed a significant reduction of 
mortality and venous thromboembolism (VTE) recurrence rate as well as 
reduced VTE related mortality47. Typically, treatment is initiated with LMWH 
parallel with VKAs, due to the observation of higher recurrence rates in patients 
receiving VKAs only48. A therapeutic range INR of 2.0-3.0 has been shown to 
be the optimal treatment intensity for patients on VKA for VTE49,50. A similar 
approach of initial combination with LMWH was used in the dabigatran VTE 
treatment studies, with comparable efficacy and better safety51-53. Two factor Xa 
inhibitors were, however, shown to be as effective when given at an increased 
dose for the first 1-3 weeks without the need of an initial treatment period with 
LMWH54,55, simplifying the management of VTE patients. The optimal duration 
of anticoagulation in VTE is still discussed, and several factors are argued to 
affect this decision including age, sex, body mass index, the site of VTE, 
whether the patient has had a previous VTE or not, the presence or absence of 
provoking factors, thrombophilia, and other persistent risk factors as cancer1 The 
DOACs are also as effective as LMWH in preventing VTE after major 
orthopedic surgery56-62. Dose adjusted warfarin therapy has also been shown to 
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be effective in reducing the incidence of post-operative venous 
thromboembolism63. 
 
Prosthetic heart valves 
Mechanical prosthetic heart valves (PHV) are associated with an increased risk 
of both valvular thrombosis and stroke/systemic thromboembolism64. Most of 
the data available in the literature is based on follow-up of patients with older 
PHV models, and the risk of thromboembolic complications with the new 
models is likely to be lower65. Treatment with VKAs appears to drastically 
reduce the risk of these events by up to 90% at the price of increased bleeding 
risk66. Patients with combined prosthetic aortic and mitral valves appear to be at 
the highest risk of thromboembolism, followed by implants at the mitral and then 
the aortic positions65,67. Consequently, a higher anticoagulation intensity (INR 
range 2.5-3.5) is generally recommended for patients with mitral valve 
prosthesis67. Vitamin K antagonists seem to be more effective than low 
molecular weight heparins (LMWH) for long term anticoagulation of patients 
with PHV, but the evidence supporting this comes mainly from pregnant women 
with PHV68.  The use of LMWH during pregnancy is advocated by some due to 
the increased risk of congenital malformations related to the teratogenic effect of 
VKA69,70. Recently a study comparing DTI dabigatran at doses adjusted 
according to plasma concentration with standard VKA therapy for patients with 
PHV was terminated prematurely du to an excess of thromboembolic and 
bleeding complications in the dabigatran arm71.  
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Other indications 
Warfarin is efficacious in a number of other conditions. In patients with acute 
coronary syndrome the use of warfarin as single therapy or in combination with 
aspirin is beneficial72,73 leading to more substantial risk reduction compared with 
the addition of clopidogrel to aspirin. The high bleeding risk seen with 
combinations of warfarin and antiplatelet agents has probably let to limited use 
of such therapy compared to the aspirin-clopidogrel combination.  
Warfarin is also used in patients with primary pulmonary hypertension to 
prevent the formation of small thrombi in the pulmonary arterial tree that might 
lead to further disease progression74. However, the evidence for this indication 
for warfarin is not strong75 
 
 BLEEDING COMPLICATIONS  
Bleeding is the most serious complication of treatment with anticoagulants.  
Generally, bleeding complications are reported in clinical studies as minor, 
clinically relevant but non-major, major or fatal bleeding. There were no 
standardized definitions for these types of bleedings making it difficult to perfom 
indirect comparisons between different anticoagulants76. Later on, the 
International Society on Thrombosis and Hemostasis (ISTH), developed 
standardized criteria for the definition of major bleeding in clinical trials77, and 
these criteria have been used in most non-surgical studies on the DOACs but in 
the surgical studies there were important differences in the definition.  
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Incidence of major bleeding complications on anticoagulants: 
As mentioned above, the definitions of “major” and “minor” bleeds were 
somewhat different in the studies. This together with difference in treatment 
indication and patient’s characteristics contributes to the variation in bleeding 
rates reported. It is also important to keep in mind the background risk of major 
bleeding in the respective patient group, i.e. the risk of bleeding events in 
comparable patients who are not on treatment with anticoagulants. 
A review of published studies reported annual rates of fatal, major, and 
major/minor bleeding of 0.6%, 3.0%, and 9.6% respectively78. In a pooled 
analysis of five trials on the effect of warfarin in patients with AF, the annual 
incidence of major bleeding on warfarin was 1.3%, which represents a modest 
increase of the risk of bleeding compared to the control arm (1%) with an annual 
attributable risk of only 0.3%38. Recently, a meta-analysis including data from 
over 300,000 patients reported a pooled estimate of the rate of major bleeding of 
2.51 (99% confidence interval: 2.03–3.11) bleeds per 100 patient-years79. 
Another meta-analysis of studies on warfarin treatment due to VTE, that 
compared bleeding rates in a group who discontinued warfarin after “short-term” 
treatment to those that discontinued warfarin after “long term” treatment” 
focusing on the period from the discontinuation of warfarin in the first group to 
the discontinuation in the second group reported almost a doubling of the 
bleeding rates in the group that continued treatment (0.6% vs. 1.1%)80  
Intracranial hemorrhage (ICH) is the most feared type of anticoagulants related 
bleeding events, with mortality rates as high as 68% and considerable morbidity 
in patients surviving the bleeding event81. In a pooled analysis of the five major 
AF trials, the annual rate of ICH in the active VKA treatment group was 0.3%, 
compared to 0.1% in the control group38, but another study showed a more 
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drastic increase in the risk82. Specifically intracerebral hemorrhage (ICeH) was 
shown to have the highest mortality rates of all types of ICH while subdural 
hematoma (SDH) has the highest recurrence rates83. One of the main advantages 
of the DOACs is the significant reduction of rates of ICH across all the phase III 
trials on these agents43-46. 
Gastrointestinal bleeding (GI bleeding) is the commonest type of major bleeding 
complicating treatment with anticoagulation. In one study GI bleeding in VKA 
treated patients occurred with an annual rate of 4.5% and was associated with a 
significant increase in morbidity and mortality84. The DOACs seem to be 
associated with higher rates of GI bleeding43-46, probably due to higher 
concentration of these drugs in the GI tract, caused partly be the lower 
bioavailability and partly by the fact that excretion of these drugs into the GI 
lumen through the P-gp system is one of the elimination routes.  
One detailed review of studies including patients who were carefully monitored 
for VKA treatment concluded that VKAs increase the annual risk of extra-
cranial bleeding by 0.3-0.5% and of ICH by 0.2% compared to controls85.  
 
Predictors of bleeding events on oral anticoagulants 
Several factors have been associated with an increased bleeding risk in patients 
on anticoagulants, including the intensity of anticoagulation, the characteristics 
of the patient, other interacting/potentiating drugs and the duration of treatment. 
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The intensity and stability of anticoagulation 
 
a. The target INR 
Randomized trials have repeatedly shown that higher target INR with VKA 
treatment is associated with an increased bleeding risk, regardless if the patient 
was on VKA for VTE17, mechanical heart valves86-90or AF91-93. Targeting an 
INR of >3.0 was associated with doubling or the risk of major bleeding 17,87,89,90, 
and specifically, the risk of ICH doubled with each 1 unit increase in the targeted 
INR14. 
b. Actual INR 
The actual INR intensity has been strongly related to the bleeding risk94, and 
especially to the risk of ICH, which seems to increase sharply above INR of 
465,95. 
c. Time in therapeutic range (TTR) 
The percent time in therapeutic INR range is a way of summarizing the quality 
of anticoagulation over time96. Patients with low TTR, reflecting a large 
variation in the INR over time, are at a higher risk of VKA related major 
bleeding, probably because they spend longer time in the supra-therapeutic range 
compared to patients with high TTR 16,97-99 
 
Duration of treatment 
Several studies have reported a higher incidence of bleeding events early in the 
phase of introducing VKAs compared to the later treatment period15,16,100,101. 
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First month bleeding rates of up to 3%, dropping to only 0.8% per month for the 
rest of the first year, and thereafter down to 0.3% per month were reported in one 
study100. 
 
Patient characteristics 
 
a. Age 
Most of the evidence for the effect of age on the bleeding risk while on 
anticoagulants comes from SPAF studies. A number of studies identified 
increased bleeding risk with age98,102-105. Age above 75 years was found to be an 
independent predictor of increased bleeding risk both in patients on warfarin 
(Relative risk, 6.6; 95% confidence interval [CI], 1.2–37; p = 0.032)105 and in 
those on DOACs like dabigatran106. There also seems to be an interaction 
between supratherapeutic INR and old age, especially for ICH, resulting in a 
more significant increase in the risk of ICH for a given supratherapeutic INR as 
compared to younger patients107,108. The odds ratio (OR) for ICH in patients 
older than 85 years is 1.3 (95% CI, 0.8 –2.2) compared to those 70-74 years old 
at an INR range of 2.0-3.0; however the OR for the same comparison increases 
significantly to 2.5 (95% CI, 2.3–9.4) at an INR range of 3.5-3.995. 
b. Gender 
Studies have reported conflicting results on the effect of sex on the bleeding risk 
with the oral anticoagulants109,110. Women appear to have a higher incidence of 
minor bleeding while on oral anticoagulants98, but the incidence of major 
bleeding seems to be similar in both sexes98,105 
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c. Previous bleeding 
A history of previous bleeding has been shown to be a risk factor for new 
bleeding events111-113. Specifically a history of gastrointestinal (GI) bleeding 
predicts a new GI bleeding in the setting of anticoagulants 114, but this could not 
be confirmed in other studies91,107,115. It is also unclear if the changing panorama 
of peptic ulcer disease with the introduction of eradication therapy for 
helicobacter pylori would affect this risk factor. A history of a non-bleeding 
peptic ulcer has not been shown to increase the risk of recurrent GI 
bleeding16,115. For ICH, SDHs have been shown to carry a high recurrence rate83. 
d. Renal impairment 
Patients with renal impairment represent a challenge for treatment with oral 
anticoagulants, both with the old and the new agents. Several guidelines list 
impaired renal function as a risk factor for bleeding on anticoagulants85,116, 
although this association was only weak in other studies16,20,107. A systematic 
analysis of published data on the bleeding rates in patients with renal impairment 
and hemodialysis did not identify studies with comparison arm including patients 
with warfarin therapy and normal renal function, and all comparisons were made 
with historical data limiting the quality of the evidence117. To date, no 
randomized controlled trials have addressed this question properly.  
The DOACs are all more or less dependent on renal function for elimination36. 
Therefore, renal impairment would at least theoretically increase the risk of drug 
accumulation and thereby increasing the bleeding risk. Indeed, renal impairment 
(estimated glomerular filtration rate [eGFR] less than 30 or 25 ml/minute) was 
an exclusion criterion in all phase III trials investing these agents. This trend of 
increased bleeding risk was shown in subgroup analysis of all the phase III 
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trials118. However, in one post-hoc analysis of major bleeding events in the 
RELY trial, which compared dabigatran and warfarin for SPAF, impaired renal 
function was not an independent risk factor for bleeding106 Similarly, in the 
SPORTIF trial that compared the oral thrombin inhibitor ximelagatran and 
warfarin for SPAF, renal impairment was not an independent risk factor for 
bleeding after multivariate analysis. In one study with the factor Xa inhibitor 
rivaroxaban, patients with moderate renal impairment had increased bleeding 
risk as compared to those with normal renal function119. 
In another population-based trial, patients with AF and renal impairment, had 
increased rates of bleeding, regardless if they were treated with VKA or not; 
furthermore, the increase in bleeding risk seemed to be similar in both groups120. 
This illustrates the importance of having a comparison arm and can at least 
explain some of inconsistencies between the different trials.  
In summary, there is no strong evidence that renal impairment is an independent 
risk factor for bleeding in patients treated with anticoagulants, especially for 
those on vitamin K antagonists. 
e. Other comorbidities 
Hypertension was found to be associated with an increased bleeding risk, 
especially ICH100, with an associated relative risk of 3.4, p=0.05. In this study, 
the incidence of ICH was 7% in patients with a history of blood pressure 
>160mmHg compared to only 1% in patients with a history of blood pressure 
140-159mmHg. Other studies have also found a similar association between 
major bleeding (regardless of the location) and hypertension 121, including even 
“treated hypertension”85. 
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Hospitalization for alcohol-related diagnosis within the past 18 months was 
found to be an independent risk factor for readmission for bleeding in one study 
(relative hazard 2.6, 95% CI: 1.4 to 4.8)113. Other risk factors identified by 
studies include cerebrovascular disease107, ischemic stroke20,102, and serious heart 
disease107. A history of diabetes has been associated with an increased bleeding 
risk on anticoagulants85, though this has been challenged by a more recent 
study109.  
The presence of malignancy has been strongly associated with an increased 
bleeding risk in several studies113,115,122, and is related to the stage of the 
disease123 but not to the degree of anticoagulation25,123. Indeed, the finding of 
higher bleeding rates and lower efficacy of VKAs compared to LMWH for 
patients with VTE and cancer has been the basis for recommending against the 
use of VKAs in cancer patients124. 
f. Pharmacogenetic factors 
The cytochrome P450 CYP2C9 enzyme is responsible for the metabolism and 
the hydroxylation of the S-enantiomer of warfarin125, and polymorphism of this 
enzyme have been identified. Two variants of the enzyme CYP2C9*2 and 
CYP2C9*3 seem to be associated with a slower metabolism of VKA and the 
need for lower doses to achieve therapeutic INR126 and were also associated with 
higher incidence of major and minor bleeding in some studies127-129. Similarly, a 
polymorphism in the VKORC1 enzyme has also been shown to be associated 
with the need for lower dose of VKA130, which might also be associated with an 
increased bleeding risk.   
Another type of polymorphism affecting platelet glycoprotein IIb/IIIa, a receptor 
for fibrinogen that is important in platelet activation, has been associated with a 
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significantly increased risk of bleeding in a cohort of patients with VKA and 
antiplatelet therapy for ventricular assist device, even though the VKA dose, the 
INR levels and the platelet tests were not affected by this polymorphism131 
g. Other concomitant drugs 
Vitamin K antagonists are known to interact with a large number of drugs132,133, 
affecting the pharmacokinetics and pharmacodynamics of VKAs, and 
necessitating more frequent control of INR when one of these drugs is 
administered during VKA therapy. 
While VKAs affect the “plasma coagulation”, antiplatelet agents further inhibit 
the coagulation process by blocking the primary hemostatic system. In a Danish 
study investigating the risk of non-fatal or fatal bleeding in combination therapy 
with warfarin, the risk of bleeding was doubled with the addition of aspirin, 
tripled when adding clopidogrel, and quadrupled when adding both aspirin and 
clopidogrel to warfarin therapy134. A meta-analysis found similar results135. In 
another meta-analysis, the risk of ICH doubled (RR, 2.4; 95% CI, 1.2– 4.8; 
p=0.02) when warfarin was combined with aspirin136. Data from several other 
studies were consistent with the above results of an increased risk of major or 
minor bleeding when antiplatelet therapy was added to VKAs85.  
In a recent post-hoc analysis of data from the RELY study, looking at the 
bleeding risk when antiplatelet agents were combined with the new agent 
dabigatran, a similar trend of doubling of the bleeding risk was noticed137.  
Similar results were seen in a pooled analysis of phase I and II studies in patients 
with myocardial infarction and combination therapy with antiplatelet and the 
DOACs138. 
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Non-steroidal anti-inflammatory drugs (NSAIDs) are associated with an 
increased risk of bleeding, specifically upper GI bleeding and peptic ulcer 
bleeding139. Several studies140, including registry studies141,142, have shown that 
the addition of NSAIDs to VKAs increased the risk of upper GI bleeding by 
more than three times.  Data on the concomitant use of NSAIDs and the DOACS 
are scarce with some studies reporting an increased bleeding risk143, while others 
did not show such an increased risk144 
Selective cyclooxygenase 2 (COX2) inhibitors are theoretically associated with 
lower rates of bleeding, and specifically lower GI bleeding rates, since they 
selectively inhibit COX2 resulting in less platelet inhibition and less gastric 
mucosal injury. Studies investigating the bleeding risk in patients receiving 
concomitant COX2 inhibitors and VKAs yielded diverging results, with some 
showing a similar, 2-3 fold increase, risk of GI bleeding compared to NSAID145, 
and others failing to show an increased bleeding risk with such 
combinations146,147. 
There is currently a wealth of evidence that the use of paracetamol with VKAs 
causes a modest increase in the INR values148,149, and is a risk factor for 
excessive anticoagulation150. One study reported an excess of upper GI bleeding 
in patients taking paracetamol and VKAs141, although adjustment for 
comorbidities necessitating the intake of paracetamol in this group was not done, 
which limits the quality of the evidence.  
 
Impact of bleeding on patient outcome 
Bleeding carries the risk of increased immediate morbidity and mortality when 
occurring in the setting of anticoagulation. In addition, it seems to be 
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associated with poorer long-term outcome151. There are several explanations to 
these results; first, such bleeding events are usually managed by 
discontinuation of anticoagulation, either temporarily or permanently, which 
exposes the patient to an increased risk of thromboembolism152. Second, many 
of the factors that precipitate or predict a bleeding event are at the same time 
predictors of increased morbidity and mortality153. Third, anemia resulting 
from the bleeding leads to poorer outcome independent of the direct effect of 
bleeding itself154. Last but not least, transfusion of blood products has been 
shown to carry increased risk of adverse events, including volume overload, 
acute lung injury, infection transmission and is generally associated with 
poorer prognosis155-157, and not always associated with improved survival158-
160. 
 
Reversal of anticoagulation 
In certain situations, as in the case of major bleeding or before an emergency 
invasive procedures or surgery, a rapid reversal of the effect of anticoagulants is 
needed to limit the bleeding or to allow safe surgery.  Several reversal methods 
are available, and can be classified as non-specific supportive measures or 
specific reversal strategies. The choice of strategy depends on several factors 
including the intensity, type of and the indication for anticoagulation, the use of 
other hemostatic agents that can affect the coagulation system, the rapidity with 
which reversal is needed, patient characteristics, the severity and location of 
bleeding or the type of intervention needed. One of the risks of these reversal 
strategies is pushing the balance in the coagulation system towards the 
thrombotic side exposing the patients to an increased risk of thromboembolism. 
Therefore a careful choice of the reversal strategy is needed to avoid any adverse 
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events.  
The “specific” reversal strategies available for the reversal of anticoagulants can 
be further subgrouped. Few anticoagulants have “specific antidotes”. Vitamin K 
can be used to competitively overcome the VKAs, allowing for the synthesis of 
functional vitamin K dependent coagulation factors. Protamin is a strong basic 
substance that binds to and inactivates the acidic heparin. Other specific reversal 
strategies involve administration of readily available coagulation factors, e.g. 
prothrombin complex concentrate (PCC) or plasma for the reversal of VKA 
effect. A third group includes the bypassing agents recombinant activated factor 
VII (rFVIIa), and activated PCC (APCC). Finally, compensatory pro-hemostatic 
agents to improve coagulation (desmopressin) or to reduce fibrinolytic 
breakdown of the hemostatic clots (e.g. tranexamic acid) can be utilized as 
adjuncts. 
 
Assessment of the intensity of anticoagulation 
In case of vitamin K antagonists, the standardized method for measuring the 
degree of anticoagulation is the PT, expressed as INR which can be performed as 
a point of care analysis in many emergency department, allowing for 
instantaneous assessment of the intensity of anticoagulation, or at a central 
laboratory. INR is standardized based on the ISI of the thromboplastin used in 
the local laboratory as discussed before13. 
Measurement of the degree of anticoagulation with the DOACs is more 
challenging: to start with, there are several drugs and classes of DOACs, and the 
different agents affect the coagulation system differently. There is no single 
standard test that can be used for all these agents, which makes prior information 
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on the specific drug used by patient in question essential for the measurement. 
Most of the tests that can measure the level of anticoagulation in patients on 
DOACs are still not widely available, and the non-specific tests (PT, INR, 
activated partial thromboplastin time [APTT], thrombin time, non-standardized 
anti-Xa) are affected differently by DOACs and normal results of these analyses 
do not completely exclude the presence of therapeutic concentrations of the 
DOACs161,162.  Considering the relatively short half-life of the DOACs, the level 
of anticoagulation, and subsequently the effect on the coagulation system and 
laboratory tests, is also dependent on the time since the last intake of the DOAC. 
In case of the DTI dabigatran, the best commercially available test to assess 
therapeutic or toxic levels of the drug is diluted thrombin time (Hemoclot®)163. A 
number of additional laboratory tests can also be used for accurate measurement 
of dabigatran level163, but these tests are less available. Other tests give a more 
semi-quantitative evaluation; APTT has a linear correlation with the plasma 
concentration of dabigatran until therapeutic levels, beyond which it flattens 
out161. A normal APTT is therefore useful to exclude clinically important 
concentrations of dabigatran, but APTT is not useful to measure supratherapeutic 
levels. 
For the factor Xa inhibitors (rivaroxaban, apixaban, edoxaban, and betrixaban), 
the use of chromogenic anti-Xa assay with drug-specific calibrators offers a 
quantitative way of assessing the level of anticoagulation164,165. The PT was 
found to be sensitive for the plasma concentration of rivaroxaban166, but the 
result should not be transformed into INR for measuring the level of the Xa 
inhibitors, since INR is specifically designed for use with VKAs, and this 
calibration makes it less sensitive to the Xa inhibitors. A later study concluded 
that APTT was more sensitive than PT for rivaroxaban levels, but the effect of 
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low levels of rivaroxaban on the APTT was weak, therefore normal APTT 
cannot be used to exclude therapeutic concentrations of the oral Xa inhibitors162. 
Prothrombin time is less sensitive for apixaban than rivaroxaban and should not 
be used to assess the level of the former167. 
 
Non-specific measure 
General supportive measures should be employed for all patients presenting with 
bleeding, regardless the cause or drug being used by the patients.  They generally 
aim at giving circulatory support, reducing the level of drug exposure, and 
improving the hemostasis. Anticoagulants, and even concomitant antiplatelet 
drugs, should be temporarily discontinued in the event of a major bleeding. 
General support of the circulation involves securing vascular access. Very 
careful consideration of the use of plasma expanders is encouraged as these 
agents might further disturb the coagulation by dilution of the different 
components of the hemostatic system. The administration of red cell 
concentrates, plasma and platelets according to a pre-specified ratio (4:4:1) has 
been seen to reduce mortality in massive hemorrhage in trauma, probably by 
preventing hemodilution and consumption coagulopathy168.  
Reduction of absorption of the ingested drug through the administration of 
activated charcoal can be used in cases of intoxication if the drug intake was 
within 2-3 hours before presentation169,170. Gastric lavage can also be used in this 
setting, though it caries a greater risk of aspiration in a patient with depressed 
level of consciousness. Enhancing drug elimination buy ensuring adequate 
diuresis is of particular importance in case of the DOACs which are more 
dependent on renal route of elimination than VKAs. Diuresis dose not reduce 
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drug exposure nor increase glomerular filtration, but it may reduce tubular 
reabsorption of these drugs36. 
Dabigatran has a low plasma protein binding (35%) and therefore, in case of 
serious bleeding or intoxication, hemodialysis can be used to remove the drug. 
Animal models have shown that the use of activated charcoal perfusion dialysis 
can reduce the drug level 75-80% after 1 hour of dialysis169. In another study and 
based on drug concentration in inlet and outlet dialysis lines, 62% and 68% of 
the drug was removed after 1 and 2 hours of dialysis respectively171. Several case 
reports have demonstrated the efficacy of this method in managing life 
threatening bleeding on dabigatran172-175. Dialysis is not effective in removing 
the Xa-inhibitors, which are highly bound to plasma proteins. 
Several non-specific measures can be used to improve the hemostasis. 
Mechanical measures can be used to reduce blood loss, including compression of 
the bleeding vessel, surgical intervention to ligate bleeders, or endoscopically 
managing bleeding site, e.g. by adrenalin injection to a bleeding ulcer. Thrombin 
or fibrin glue can also be applied locally to reduce blood loss. When bleeding 
sites are not easily accessible, coiling of the bleeding vessel can be used. 
Antifibrinolytic agents, such as tranexamic acid and epsilon amino-caproic acid, 
act by competitively binding to and blocking the active site of plasminogen, 
preventing its conversion to plasmin. These agents have been shown to be 
effective in reducing the blood loss in cases of trauma176 and different types of 
surgery177,178 without an increased risk or thromboembolism. Local use of 
tranexamic acid is effective in preventing excessive blood loss after tooth 
extraction in patients on warfarin therapy179. No studies have specifically looked 
at the role of antifibrinolytic agents in case of bleeding related to anticoagulants, 
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but their use in this setting should be encouraged due to their safety.  
Acidosis, hypocalcemia, anemia, and hypothermia have all been shown to affect 
the hemostatic system negatively, and should be corrected promptly in the 
bleeding patient180.  
 
Specific hemostatic agents and antidotes 
 
1. Vitamin K 
Vitamin K1 (phytonadione, phytomenadione) and vitamin K2 (menaquinone) 
occur naturally in certain foods and vitamin K2 variants are also produced by 
some of the intestinal flora. It can either be administered orally or intravenously 
and can reverse the effect of VKAs by replenishing the vitamin K depots. 
Intravenous administration is rarely (3/100 000) complicated by anaphylactic 
reactions181.  Oral administration is not recommended in patients with 
malabsorption or biliary obstruction. Full effect is only achieved after 12-24 
hours, making vitamin K unsuitable as the only treatment for patients with 
serious bleeding related to VKAs.  Doses of 0.5-1mg seem to be enough to 
correct supratherapeutic INR to therapeutic range faster than only adjusting 
VKA dose and is associated with minimal risk of overcorrection182 . In one study, 
treatment with low doses of vitamin K also led to lower bleeding rates183 . Higher 
doses might be associated with “warfarin resistance” up to a week. However, 
such high doses of 5-10mg are recommended for patients with a serious bleeding 
event, with very high INR or with liver diseases5 .  
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2. Plasma 
The use of plasma for the reversal of the effect of warfarin is still debated184. 
Plasma transfusion for the reversal of anticoagulation carries the risk of infection 
transmission, acute lung injury, volume overload, and incomplete 
anticoagulation reversal155-157. It is time consuming due to the need of ABO 
blood group compatibility, thawing and the need for transfusing a large volume 
for effective reversal155. In one study, the mean time to correction of INR with 
plasma transfusion for warfarin related intracranial hemorrhage was 30 hours185, 
making it a less than ideal choice for the reversal of anticoagulation. Plasma, 
however, has a physiological, balanced combination of coagulation factors when 
administered as a fresh product. It is mainly useful in patients with large loss of 
volume or when the initial bleeding is complicated by hemodilution and 
consumption coagulopathy due to volume substitution with iv fluids186,187. No 
trials have investigated the use of plasma as the only reversal agent for the 
DOACs. 
 
3. Prothrombin complex concentrates (PCC) 
Prothrombin complex concentrates are lyophilized, heat or solvent-detergent 
treated, nano-filtrated concentrates of vitamin K dependent coagulation factors 
(factor II, VII, IX, and X) produced from human plasma. They can be divided 
into APCC containing both non-activated and low levels of activated vitamin K 
dependent factors, and non-activated PCC. Another way of classifying PCC 
depending on their level of factor VII, is 3-factor PCC containing low levels of 
FVII or 4-factor PCC with higher level of FVII. Some brands of PCC contain 
also anticoagulant proteins C, S and Z, as well as antithrombin, a low 
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concentration of heparin and sodium citrate. The addition of these substances 
aims at reducing the thromboembolic risk associated with the administration of 
PCC49. PCC are standardized according to their factor IX levels. Compared to 
plasma, PCC have a 25 times higher concentration of vitamin K dependent 
factors, thereby reducing the necessary volume to achieve similar effect by 25 
times188, PCCs are non-blood group specific, readily available at room 
temperature without the need of thawing, and these properties mean that PCC 
can be given more rapidly than plasma to treat serious bleeding. Several PCCs 
are available in different countries for the reversal of VKAs157. 
In patients with acquired deficiency of vitamin K dependent factors, the 
administration of PCC rapidly corrects the plasma levels of these factors. In a 
controlled trial, the INR was corrected to under 1.3 at 30 minutes after the end of 
infusion in 62% of patients on VKA treated with PCC compared to only 9.6% 
who received plasma189. It is, however, unclear if this more rapid reduction of 
INR can be translated into an improvement in morbidity and mortality, 
especially in patients with ICeH, where the more rapid reversal of 
anticoagulation can theoretically limit the expansion of the hematoma, which has 
been shown to be related to the disability and mortality after such bleeding190-195. 
There is a fear of the use of PCC because of the risk of thromboembolic events 
complicating their use157, but the magnitude of this risk is still not well 
determined.  
Data on the use of PCC for the reversal of the DOACs are emerging. In one trial 
in healthy individuals given dabigatran or rivaroxaban, PCC was able to correct 
laboratory abnormalities induced by rivaroxaban but not by dabigatran196. Case 
reports on patients with dabigatran related bleeding complications treated with 
PCC have been conflicting regarding its efficacy172,197. 
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Activated prothrombin complex concentrates are mainly used for the treatment 
of hemophilia patients with acquired inhibitors to coagulation factors and are 
probably associated with higher risk of thromboembolic complications than 
PCC198. They are not used for the reversal of VKAs, but recent publications have 
shown promising results for the reversal of the DOACs, especially dabigatran, 
with APCC199-201. In a recent publication, four patients with life-threatening 
bleeding were managed successfully with APCC202. 
 
4. Recombinant activated factor VII 
Recombinant FVIIa (rFVIIa, NovoSeven®, NovoNordisk, Denmark) was 
initially developed for the management of bleeding in patients with hemophilia 
and acquired coagulation factor inhibitors, but its off-label use has rapidly 
expanded. Several studies have demonstrated the efficacy of rFVIIa in the setting 
of VKA-associated bleeding, at least for correcting INR rapidly203-206. The use of 
rFVIIa for this indication is, however, not recommended due to the significantly 
increased risk of arterial thromboembolic events207. 
The limited experience from the use of rFVIIa for dabigatran bleeding has not 
been encouraging. It was not effective in limiting the bleeding in animal 
models208, nor in correcting laboratory abnormalities induced by another DTI, 
melagatran, in healthy individuals209. It has not either shown convincing 
evidence of efficacy in a few case reports172,173.  
The use of rFVIIa for the reversal of factor Xa inhibitors is very limited, and 
most data available come from animal models, which have shown correction of 
laboratory abnormalities without a clear effect on the bleeding volume210,211. 
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5. Specific antidotes 
Specific antidotes have been developed recently to reverse the anticoagulant 
action of the DTI dabigatran and the Xa inhibitors using different approaches. A 
highly selective humanized monoclonal antibody fragment (Fab) against 
dabigatran was developed by Boehringer Ingelheim, Germany, and is currently 
in phase II studies in patients with dabigatran-related bleeding or who are in need 
of emergency surgery. The antibody binds selectively to dabigatran and has no 
other effects on the coagulation system. It has a rapid dose-dependent effect 
lasting up to 6 hours after intravenous injection and has been shown to reverse 
the anticoagulant effect of dabigatran ex-vivo as well as reduce the blood loss in 
a rat-tail injury model212. 
A recombinant modified factor Xa (PRT4445) that has a high affinity to the Xa 
inhibitors has been developed as an antidote to several oral and parenteral Xa 
inhibitors. By binding to these anticoagulants, it prevents them from binding to 
the native active factor X. The structural modification in this recombinant Xa 
decoy renders it inactive in the coagulation pathway. PRT4445 was shown to be 
well tolerated in healthy volunteers and with rapid (5min) and sustained (3 
hours) effect. In preclinical studies, PRT4445 was shown to be effective in 
reversing the effect of betrixaban, fondaparinux and enoxaparin36. 
Recently, a universal anticoagulant-reversal agent has been developed by 
Perosphere; PER997 is a small molecule that can bind to and inactivate several 
of the novel oral agents, including dabigatran, rivaroxaban, apixaban and 
edoxaban. Rat-tail injury models have shown the ability of PER997 to reduce 
blood loss in animals treated with the above anticoagulants. It dose not affect 
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commonly used coagulation test and has no effect on the coagulation system in 
patients not taking anticoagulants. Clinical trials are now underway for the 
evaluation of the efficacy of PER99736. 
 
Restarting anticoagulation after bleeding 
In patients suffering a major bleeding event while on anticoagulants, and in spite 
of the underlying increased risk of thromboembolism that warranted 
anticoagulation in the first place, the use of anticoagulants is usually 
discontinued. Depending on the indication for anticoagulation and the severity of 
the bleeding event, this discontinuation is either permanent or temporary. In the 
latter case the patient is sometimes started first on other forms of anticoagulation 
(e.g. prophylactic dose of LMWH) before oral anticoagulation is resumed.  In 
many cases of VTE, treatment can either be discontinued permanently or the 
patient can be switched to LMWH, which is as effective as and seem to carry 
lower bleeding risk than VKAs.  Patients with cardio-embolic indications for 
anticoagulation represent a special challenge, however; LMWH has not been 
systematically evaluated for the prevention of thromboembolism in patients with 
AF and this indication is not approved for LMWH. In patients with PHV 
LMWH are known to be less effective in preventing valvular thrombosis and 
systemic embolization, as discussed previously. The decision about whether to 
and when to restart anticoagulation must balance the risk of recurrent bleeding if 
the anticoagulation is restarted early after the bleeding, and the risk of a 
thromboembolic event if anticoagulation is delayed. A few number of studies 
have tried to address the question of when to restart anticoagulation after a major 
bleeding event213-220, generally including patients form one center with limited 
 32 
follow-up, and the question remains inadequately answered in the absence of 
large controlled trials or RCTs. 
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2 METHODS 
 
STUDY POPULATION AND END POINTS: 
Study I and II focused on different aspects of the management of patients with 
VKA-related ICH; hence some patients included in the Study I were also 
included in the Study II, and the two study populations were partly identical. 
Study III investigated the incidence of a particular adverse event of PCC, namely 
thromboembolism. Study IV assessed the outcome of patients receiving non-
specific supportive therapy for major bleeding related to dabigatran, in the 
absence of a specific reversal agent. The population of Study I and II was 
therefore different from Study III, and a different population was used in the 
Study IV from the other three. 
 
Study I and II 
Several centers were needed to identify a sufficient number of patients for a 
reliable analysis. The fact that PCC were-at the time of the study- not registered 
for use in Canada and that plasma was the main modality for the acute reversal 
of VKA made it possible to compare PCC and plasma for the reversal of VKA 
by including patients from Europe and Canada.  
All of the patients in the Study I (and most of those included in Study II) were 
recruited from 3 tertiary care hospitals: Karolinska University Hospital in Solna-
Stockholm, and Karolinska University Hospital in Huddinge-Stockholm, both in 
Sweden; and Hamilton Health Sciences-General Hospital, in Ontario, Canada. 
Study II also included patients from The Netherlands who received PCC for the 
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treatment of VKA- related ICeH.  The Dutch patients included in Study II were 
recruited from a tertiary referral center at the University Medical Centre 
Groningen, Groningen.  
 
  
!
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Figure 2: Population of Study I and II 
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Inclusion and exclusion criteria 
The patients were eligible for inclusion if they had a radiologically verified ICH, 
were on VKA treatment and had an INR of more than 1.5 at the time of 
bleeding. For Study II, the ICH had to be an ICeH and an additional criterion 
was that the patient must have received either PCC or plasma for the reversal of 
VKA effect to be included. Any combination of ICeH with SDH or 
subarachnoid hemorrhage (SAH) was classified as ICeH. Patients with multi-
trauma, or with hemorrhagic transformation of ischemic stroke were excluded 
from both studies. 
 
Data extraction 
Medical charts were manually reviewed for all patients admitted between 
January 2002 and December 2007 in Canada, and between January 2004 and 
December 2008 in Sweden, with a diagnosis of ICH (ICD-10 diagnosis code 
I600-I629). Data from patients with VKA-associated ICH underwent a final 
review by a third investigator. In The Netherlands, the medical charts of 
consecutive patients with VKA-related ICeH admitted between January 2003 
and December 2010 were reviewed for inclusion in Study II.  
Data regarding patient characteristics, indication for VKA treatment, risk score 
for stroke in patients with AF according to the CHADS2 score39, additional 
antithrombotic treatment, INR at presentation, cause of bleeding (spontaneous or 
traumatic), location of bleeding according to radiological investigations, and 
neurosurgical intervention were collected.  
The CT scans of all patients with ICeH that were included in the Study II were 
retrieved and the volume of the ICeH was calculated using 5-mm non-contrast 
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CT images, which were loaded into OsiriX Imaging Software, v.4.1.1 (OsiriX 
Foundation, Geneva, Switzerland). The volume of the hematoma was estimated 
by manual tracing of the perimeter with abnormal high attenuation on each CT 
slice. After all CT slices were evaluated, OsiriX Imaging Software combined the 
separate hemorrhage areas and rendered a three-dimensional representation from 
which the total hemorrhage volume was computed. One radiologist in Canada 
used this method to calculate the hematoma volume for patients from Canada 
and The Netherlands, and another radiologist in Sweden performed the 
corresponding calculations for the Swedish patients. To assess the inter-observer 
correlation, CT scans from 14 randomly selected patients were sent to both 
radiologists to independently measure the ICeH volume. The Pearson’s r-
correlation coefficient was then calculated from the volume measurements. 
Another variable of importance in Study II was the time to PCC administration; 
which was calculated as the difference between the time of debut of ICeH 
symptoms – as documented in the patient’s medical notes – and the time when 
PCC was given as noted in the transfusion records or medical notes. Since the 
administration of plasma takes longer time than PCC due to the volume of 
plasma needed for the reversal, the time to administration in the plasma group 
was calculated as the time from the onset of ICeH symptoms until the time when 
the transfusion of plasma was completed, as maximum effect of transfused 
plasma on the INR would be expected first when the whole volume of plasma 
was given. 
 
End points 
From the follow-up period after ICH, we collected data on the resumption of 
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warfarin, recurrent ICH, ischemic stroke, systemic embolism, transient ischemic 
attacks, heart valve thrombosis, VTE, death, and the timing of these events in 
relation to the index ICH. Data were retrieved from electronic hospital records 
and by contacting each patient’s family physician. 
Recurrent ICH was based on the radiological finding of a new ICH or expansion 
of the previously known ICH, performed due to new symptoms or deterioration 
of neurological status. Hence, the diagnosis of a recurrent ICH required a 
combination of new symptoms and new radiological findings. This was done to 
mimic the clinical setting where regular follow-up imaging is not always done 
without new symptoms. Similarly, the diagnosis of ischemic stroke had to be 
based on new neurological symptoms together with supportive radiological 
findings. We assessed the burden of recurrent ICH and ischemic stroke to be 
fairly similar when analyzing the optimal timing of resumption of 
anticoagulation. The occurrence of systemic embolization had to be objectively 
verified by imaging. 
We used the 30-day all-cause mortality in the analyses of Study II, and did not 
use the cause-specific mortality as such classification is not always very reliable 
nor easy to do when the medical notes are reviewed retrospectively. 
 
Study III 
The population of Study III was recruited from centers spread over half of 
Sweden between February 2002 and October 2010. The patients were considered 
for inclusion when the Coagulation Unit at Karolinska University Hospital was 
contacted for advice on the dose and administration of PCC.  
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Dose recommendations for PCC were based on body weight, the actual INR and 
the severity of the bleeding/type of intended intervention. Dose calculation was 
according to the method described in a previous publication221, but the actual 
given dose and any additional reversal with vitamin K or plasma was always 
decided by the local treating physician.  
The investigator at the Coagulation Unit recommended checking the INR 30 
minutes after the administration of PCC. In reality, not all the patients had their 
INR taken exactly 30 minutes after PCC infusion, and some others had several 
INRs after PCC administration e.g. in case of incomplete correction of INR to 
the desired level. We also recommended daily INRs after the successful 
correction.  
 
Inclusion and exclusion criteria 
Patients were included in the study if there was documentation in their medical 
journal of the transfusion of PCC for the reversal of VKA effect either because 
of a serious bleeding event or before urgent surgery. Treatment with PCC for 
other coagulopathies was an exclusion criterion.  
 
Data extraction 
The medical journals of patients included were requested a month after the major 
bleeding event. Data on the patient characteristics, indication of VKA, the 
bleeding location and severity, actual dose of PCC given, the use of different 
blood products, or vitamin K for the reversal of VKA effect, INR before and 
after given PCC, type of surgery performed-if any, length of stay in hospital, the 
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effect of given PCC in reversing the effect of VKA and controlling bleeding or 
preventing bleeding after a surgical intervention, the occurrence of 
thromboembolic events and death were collected from the charts. 
 
End points 
The main safety endpoint was the occurrence of arterial (stroke, myocardial 
infarction or peripheral thromboembolism) or VTE (DVT or pulmonary 
embolism) with 7 days after PCC administration, and depending on the 
identification of such events, the safety of PCC was judged as “good” or “poor”. 
The event had to be objectively verified, and two investigators independently 
reviewed the medical journals for the occurrence of these events. We used this 
“7-day rule” to identify events that were likely to be directly related to PCC 
administration and the rationale for using the 7 days cut-off was based on the 
half-life of the different coagulation factors included in PCC and to allow for 
some time for the event to be diagnosed.  
A secondary outcome in the study was the assessment the hemostatic effect of 
PCC. Two different measures were used, the first and main one was assessment 
of the clinical effect of PCC in stopping the bleeding, as judged by changes in 
hemoglobin level, the need for transfusion of blood products and intravenous 
fluid, or cessation of continued bleeding clinically or radiologically. In case of 
emergency surgery, the effect of PCC was judged depending on the amount of 
peri-operative bleeding documented versus the expected bleeding, and the actual 
need of blood transfusion versus the expected from the type of surgery 
performed. Three levels of “clinical efficacy” were used; “good efficacy” if the 
bleeding stopped shortly after PCC infusion and without the need of further 
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blood transfusion, “poor efficacy” if the bleeding and the need of blood 
transfusion continued after PCC or if the bleeding resulted in death or disability; 
“moderate efficacy” was used for cases falling between these two definitions. 
The other efficacy measure was the total number of cases successfully reversed 
to the desired INR level after PCC administration. The main focus was, however, 
on the clinical outcome rather than the surrogate laboratory end point. 
 
Study IV 
The efficacy of dabigatran as an anticoagulant was assessed in a number of 
phase III trials. The long term use of dabigatran versus warfarin was studied for 
SPAF (the RE-LY trial)43 and for treatment of VTE (RE-COVER I52 and RE-
COVER II 222 for the acute treatment, and RE-MEDY51 and RE-SONATE223 for 
the extended treatment of VTE). In total, these trials included more than 16,755 
patients on dabigatran and 10,002 patients on warfarin at several hundred centers 
worldwide. The RE-LY trial enrolled patients between December 22, 2005, and 
December 15, 2007. The different VTE trials included patients from April 2006 
to October 2010. These five trials constituted the basis from which cases with 
major bleeding events that met the inclusion and exclusion criteria were included 
in our study. 
 
Inclusion and exclusion criteria 
Eligible cases were those with centrally adjudicated major bleeding event, 
defined according to the ISTH definition of major bleeding77, and which occured 
either on treatment or within three days after the last dose of the study drug. This 
“three-day rule” was specifically used, after taking into consideration the half-
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life of dabigatran and warfarin, and to ensure that sufficient amount of the study 
drug was still in the circulation to be attributable for the bleeding event. The 
three-day rule was applied for any - temporary or permanent - discontinuation of 
the drug. We extended this rule to include one patient in the dabigatran arm who 
had a major bleeding event 4 days after discontinuing the drug, because the 
patient had severe renal impairment and abnormal coagulation laboratory tests 
suggestive of clinically significant circulating dabigatran level even at 4 days 
after the major bleeding event. 
 
Data extraction 
Serious adverse event narratives and bleeding event narratives for all eligible 
patients who suffered a major bleeding event were obtained from Boehringer 
Ingelheim. The major bleeding event narratives were generated automatically 
from the database at Boehringer Ingelheim using a template, while the life 
threatening bleeding narratives had been prepared manually by a medical writer. 
Two investigators examined and extracted data from the narratives on the patient 
characteristics, the use of antiplatelet agents or NSAID, the location and type of 
bleeding, treatment given for the bleeding including transfusion of blood 
products and/or other hemostatic agents, duration of hospitalization and death 
after the major bleeding event. These data were compared with and verified 
against the data in the database of each of the five phase III trials 
Renal function was assessed with the Cockroft-Gault formula for calculating the 
eGFR, using the creatinine on admission for the bleeding event. Creatinine levels 
were sometimes unavailable from the hospital records during the major bleeding 
event, and in that case the most recent creatinine prior to the event was used. We 
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also adopted a similar classification of traumatic vs. non-traumatic ICH to that 
published by Heart et al, based on any description in the case report form (CRF) 
of injury that could reasonably cause the ICH224 
 
End points 
The total resources needed for the management of the bleeding events in this 
study were assessed using data collected from the RE-LY database at the 
Population Health Research Institute (Hamilton, Canada). This database is based 
on information in the CRFs. Data collected include the number of units of the 
different blood products given for each patient and proportion of all bleeds 
treated with the different blood products, the proportion of events that 
necessitated hospital admission, the length of stay in intensive care and in step-
down unit, the decrease in hemoglobin from baseline before bleeding to the first 
obtained hemoglobin level during the event and from then to the lowest level in 
the event. Similar information was collected for the patients in the VTE trials, 
with focus on the utilization of the different blood products. We also registered 
information on death and the timing of death after the major bleeding event.  
Patients suffering ICH while on anticoagulants rarely require transfusion of large 
volume of different blood products, unless the ICH is a part of other bleeding 
events, e.g in patients with multiple trauma. We therefore also captured data on 
the degree of and resources needed for the management of disability 
complicating ICH. Information was obtained from the study database on the 
modified Rankin Scale(mRS) both initially on admission for the ICH and then 
during follow-up. Information on discharge destination was also collected as an 
indirect measure of the degree of disability after ICH. 
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STATISTICAL ANALYSES 
Variables in the different studies were tested for normality using skewedness, 
and QQ plots. We used mean values and standard deviations to describe data that 
was normally distributed and median and interquartile range for data that was 
skewed.  
For continuous variables, groups were compared using two-tailed Student t-test 
or Mann-Whitney test depending on the distribution of the sample. Categorical 
variables and proportions were compared using Chi square or Fisher’s exact test.  
When comparing two groups for a dichotomous outcome, e.g. death-yes/no, 
effect-good/poor, several methods exist for correcting for any imbalances 
between the groups in confounders that can bias the outcome of interest. These 
measures may be implemented at the design stage, such as randomization, or at 
the analysis stage as stratification or multivariate analysis. In our studies, we 
used both multivariate analysis (Study II and IV) and stratification (Study IV) to 
correct for such imbalances. 
In Study III, a modified intention-to-treat analysis was used including all patients 
who actually received PCC for the reversal of warfarin effect. The Exact method 
was used to calculate the confidence intervals (CIs) of proportions, which gives 
an asymmetrical interval with a higher upper limit than the conventional Wald 
method, but ensures better 95% coverage.  
In the Study II, a step-wise logistic regression analysis was used to assess the 
effect of reversal strategy on the mortality of patients with ICeH and at the same 
time to adjust for the imbalance of important prognostic factors between the two 
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treatment groups. The initial model was constructed with only the reversal 
method as an independent variable and the 30-day all cause mortality as the 
dependent variable. The odds ratio (OR) obtained at this stage represent the 
crude (unadjusted) OR for mortality in the plasma and PCC-treated groups. In 
the following steps, the other prognostic variables were added in a forward step-
wise manner. Adding any variable to the model corrected for the imbalance in 
the variable between the plasma and the PCC-treated group, and the resulting 
OR from the model will then be adjusted for the included variable(s). The 
associated p-value with the newly included variable is based on the Wald test 
and reflects if the newly added variable significantly impacts on the OR. The 
process of adding new variables will continue until there is no significantly 
important variable.  
Logistic regression was also used in Study IV to adjust for the variable 
differences between the warfarin group and the dabigatran group and the impact 
of these differences on the 30-day mortality in both groups.  
The effect of time-dependent variables was studies in the Study I and IV. In 
Study I, the effect of the timing of warfarin resumption after warfarin-related 
ICH on the risk of recurrent ICH or thromboembolic events was assessed using 
Cox-proportional hazards model, which also allows for the adjustment for 
difference in other variables in a similar way as the logistic regression. A model 
was fitted separately for recurrent ICH and another model for ischemic stroke. 
The time variable was divided into “periods” with reasonably constant risk of the 
event of interest. These periods and the associated risk differed between the 
recurrent bleeding model and the model for ischemic events because of the 
difference in the nature of these two outcomes.  The two models were then 
combined to obtain a “total risk” and determine the interval when such total risk 
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is lowest and therefore would correspond to the optimal period of warfarin 
resumption. The assumption in the Cox-model was that warfarin resumption at 
any time results in a constant proportional increase of the risk of ICH and a 
constant proportional reduction in the risk of ischemic events. This assumption 
was also tested for and verified in post-hoc tests.  
Kaplan Meier analysis was used to assess the unadjusted difference in the 30-day 
all cause mortality in the dabigatran and the warfarin arm, and to test for 
statistical significance (Figure 1 in the fourth study). The Kaplan Meier analysis 
was also used to test for the differences in the 30-day mortality after PCC 
treatment for ICeH with and without adjustment for the hematoma volume. 
A P value of < 0.05 was considered statistically significant. 
Different statistical software was used during the course of these studies for the 
analyses including SAS 9 and 9.3 (SAS Institute Inc., Cary, NC, USA), STATA 
12 and Microsoft Excel 2003. 
 
ETHICAL CONSIDERATIONS 
All studies in this thesis complied with the Declaration of Helsinki. Study I and 
II were approved by the institutional ethics committees in Sweden and in 
Canada. These ethics committees waived the need for patients consent to access 
the data in the medical records. For Study II, legislation in The Netherlands and 
local hospital medical ethics committee do not require approval or review of the 
protocol for retrospective studies in Dutch patients. Study III was approved by 
the institutional ethics committee in Sweden. For Study IV, all 5 phase III studies 
were approved by the local ethics committee in the countries where the studies 
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were conducted, and for our analysis of the major bleeds, the Research Ethics 
Board of McMaster University Faculty of Health Sciences-Hamilton Health 
Sciences approved the project without the need for patient consent. All data 
analyses were done on anonymous data without the possibility of tracing back 
the individual records to the patients. 
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3 RESULTS 
 
STUDY I 
 
Baseline characteristics 
A total of 3287 admissions for ICH in 2869 consecutive patients were identified 
at the three study centers during the study period. After manual screening of the 
medical records of all admissions, 234 (8.2%) patients were found to fulfill the 
inclusion and exclusion criteria. Baseline characteristics of the patients and their 
distribution according to the study center are shown in table 1 and table 2, 
respectively in the original paper. 
The indication for anticoagulation in 58% of the patients was AF. This is also 
reflected by the median age of the patients (76 years).  
 
Follow-up and mortality 
Fifty-seven patients died within the first week after the ICH, most of them (54 
patients) because of direct effect of the ICH. The remaining three suffered 
arterial thromboembolic events (2 ischemic strokes and 1 myocardial infarction) 
that resulted in fatal outcome. Intracerebral hemorrhage had the highest mortality 
within the first week (47 patients, representing 36% of all ICeH), which was 
significantly higher than first week mortality in other types of ICH (bleeding was 
fatal in the first week in 3 patients [14%] with SAH, and 7 patients [8%] with 
SDH). Mortality was higher in the ICeH group throughout the follow-up (59%) 
compared to patients with SDH (32%), and this difference was statistically 
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significant (Fig 3. Kaplan–Meier analysis, P<0.001). This group of patients with 
a fatal outcome within the first week was excluded from the analysis of the 
optimal timing for the resumption of warfarin because restarting warfarin within 
the first week is rarely considered, if at all, due to the presumed high rate of 
recurrent bleeding. 
 
 
 
 
Weeks  since  ICH
P
r
o
p
o
r
ti
o
n
  S
u
r
v
iv
in
g
Subdural
Intracerebral
Figure 3: Mortality according to the bleeding site 
(intracerebral vs. subdural) 
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The remaining 234 patients were followed for a median of 34 weeks (IQR 1–
115), and during this period 113 patients (48%) died, 57 of whom within the first 
week as mentioned above, corresponding to a median survival of 4.5 years after 
the ICH (figure 4). This high early mortality shortened the median follow-up. 
However, by excluding patients with fatal outcome in the first week as 
mentioned above, the median follow-up increased to 69 weeks (IQR 19 –144). 
The remaining 177 (first week survivors) constituted the basis of our risk-benefit 
analysis group. 
 
 
 
 
Figure 4: Mortality during follow-up in the entire cohort 
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Restarting warfarin after the ICH event 
Of the 177 patients surviving the first week, 59 patients (33%) were restarted on 
warfarin after a median of 5.6 weeks (IQR 2.6–17). The median age of those 
who restarted warfarin was 70 years (IQR 63–77), which was significantly 
younger than those who did not restart warfarin (78 years, IQR 70.5–72). A 
significantly higher proportion (p<0.001) of patients with mechanical heart 
valves  (15 [79%] of the patients with mechanical aortic valve and 7 [77%] of 
the patients with mechanical mitral valve) were restarted on warfarin after ICH 
as compared to those with AF (22 patients representing 22% of all AF patients in 
the study) or VTE (8 patients comprising 27% of VTE patients at baseline). 
Patients with PHV also resumed warfarin after a shorter period (4.6 weeks [IQR 
2.3–15] for patients with mechanical aortic valve, 3.1 weeks [IQR 2.2–14] for 
patients with mechanical mitral valve) than the 22 patients with AF who resumed 
warfarin after a median of 9.2 weeks (IQR 5.6–34). Unexpectedly, the 8 patients 
who resumed warfarin for VTE did so after only a median of 2.3 weeks (IQR 
1.7–19).  
When analyzed according to bleeding localization, warfarin was restarted in a 
higher proportion of patients with SAH (7 patients, 39% of first week SAH 
survivals) and SDH (29 patients, 38% of SDH patients who survived the first 
week) as compared to patients with ICeH (23 patients, 28% of ICeH first week 
survivals), although this difference was not statistically significant. Conversely, 
resumption of anticoagulation was earlier, after a median of 4.4 weeks (IQR 2.3–
14), in the ICeH group as compared to a median of 6.4 weeks (IQR 3.6 –26) 
after SDH.  
There was no difference in the proportion of patients with previous stroke who 
restarted warfarin (10 patients, 31%) compared to the proportion of those 
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restarted without previous stroke (49 patients, 34%). 
 
Recurrent ICH  
Of the 59 patients who restarted warfarin after ICH, 8 patients developed a 
recurrent ICH, as compared to 10 recurrences in the 118 patients who never 
resumed anticoagulation. The Kaplan-Meier analysis showed a trend (p=0.07) 
towards higher recurrence rate in the patients with SDH (16%) compared to 
ICeH (8.4%)(fig 5). None of the patients with SAH had recurrent bleeding. In 
one patient with ICeH at baseline, recurrence was as SDH. Another patient had 
an opposite sequence of presentation. The remaining ICH recurrences were all in 
the index presentation site. The cumulative risk of recurrent ICH without 
restarted anticoagulation or from the time point of resumption of anticoagulation 
is shown in Figure 1A and 1B, respectively, in Study I. 
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Thromboembolic events 
In total, there were 21 arterial and 11 venous thromboembolic events during the 
study period, regardless the status of warfarin resumption. Most of the arterial 
events (n=18) were ischemic strokes, occurring in 12 (12%) of all survivors after 
the first week in the AF group, 4 (14%) in the mechanical heart valves group, 1 
(3%) in the VTE group, and 1 (6%) in the group who had other indication for 
warfarin. The remaining 3 events were 1 transient ischemic attack, one systemic 
embolism to the brachial artery and one to the femoral artery. The group with 
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Figure 5. Recurrent ICH according to localization 
(intracerebral vs. subdural) 
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previous stroke had a significantly higher risk of recurrent ischemic event (28%) 
compared with those without (8.6%); (P=0.004). Of the 11 VTE events in the 
study, only 4 had VTE as the indication of anticoagulation before the ICH, and 
these events tended to occur early, after median of 2 weeks (IQR, 1.5–5) from 
the ICH. 
 
Risk modeling of recurrent ICH versus thromboembolic events 
Of the 177 patients who survived the first week after ICH, 45 patients had VTE 
as indication for anticoagulation. Since other management alternatives (either 
permanent discontinuation of anticoagulation or shift to LMWH, which is as 
effective for VTE treatment as warfarin, possibly with lower bleeding risk) are 
more frequently considered in patients in the VTE group versus those with 
cardiac indication for anticoagulation (AF or mechanical heart valves) we 
decided to do a risk modeling including only patients in the latter group or those 
who had a previous stroke. 
Restarting warfarin at any time after the ICH must take into account the 
increased risk of recurrent bleeding after warfarin resumption (relative to the risk 
of recurrent bleeding without warfarin resumption) and to balance that against 
the risk of an ischemic event after the index ICH and before warfarin 
resumption, during which the patient is left without anticoagulation (relative to 
the reduction of that risk after the point of warfarin resumption). In this analysis, 
we assumed that any recurrent ICH has the same clinical burden or disutility as 
an ischemic event, though this approach might be criticized (see methods and 
discussion). 
We aimed to build a statistical model that takes into consideration the observed 
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rates of recurrent ICH and of thromboembolism, according to warfarin 
resumption status and depending on the time point of warfarin resumption after 
the ICH. The model would then be used to make inferences about predicted rates 
of these events in the restarted and in the non-restarted group and for each 
proposed “warfarin resumption interval”, given a sufficiently large cohort of 
patients.  
A Cox proportional hazards model, with a time dependent variable that 
represented the point of warfarin resumption, revealed that the “risk” of recurrent 
ICH after an initial warfarin related ICH, increased dramatically by an average 
factor of 5 (hazard ration [HR] 5.57; 95% CI, 1.80–17.25; P=0.0029) after 
warfarin was restarted. At the same time, the risk of an ischemic event, 
specifically the risk of an ischemic stroke was significantly reduced by about 
90% (HR 0.11; 95% CI, 0.14–0.87; P=0.036). The assumption of proportionality 
of the rates was demonstrated by the relatively constant HR during the different 
follow up intervals, as can be seen in table 1. The HR representing the increased 
risk of ICH if warfarin was restarted before day 35 (HR=4.13) is comparable to 
that when warfarin is restarted between days 36-63 (4.46). Even though no cases 
of recurrent ICH were observed after day 63 when warfarin was not restarted by 
that time, this is most certainly explained by a lack of sufficient number of 
patients in this group and the relatively limited follow-up time rather than an 
actual absence of bleeding events in this period. To correct for this, the observed 
baseline bleeding rates in the group that restarted warfarin after day 64 and the 
assumed constant HRs in the model (HR=5.57) can be used to predict and 
replace the missing information on the bleeding rates in the group that did not 
start after day 64. A similar picture of “missing events” in the analysis of the 
thromboembolic events is seen in table 1 and can be corrected for using the same 
strategy of calculating predicted rates using the observed rates of 
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thromboembolism in the group that did not restart warfarin and with the 
proportional HR for the reduction of the risk of thromboembolism calculated 
from the Cox model (HR=0.11). This allowed us to build a complete picture on 
the risk of recurrent bleeding and on the risk of ischemic events before and after 
warfarin resumption and for different time points of warfarin resumption after 
the ICH. This final model uses therefore a combination of observed rates and 
Cox model predicted rates. 
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Table 1.1: Cox proportional hazards model for recurrent intracranial 
hemorrhage at different time intervals with and without resumption of warfarin 
Warfarin Status Risk of intracranial hemorrhage per day Events/Days of observation (rate) 
 1-35 days 36-63 days 64-217 days >218 days 
Observed rates     
No 7/3829 1/2250 0/10146 0/32208 
 (0.18%) (0.044%) (0.00%) (0.00%) 
Yes 2/265 1/504 2/4008 2/29056 
 (0.75%) (0.20%) (0.049%) (0.0069%) 
Hazard ratio 4.13 4.46 ∞ ∞ 
Rates used in prediction model*   
No 0.18% 0.044% 0.0090%† 0.0012%† 
Yes 1.02%‡ 0.25%‡ 0.049% 0.0069% 
 
 
Table 1.2: Cox proportional hazards model for ischemic event at different 
time intervals with and without resumption of warfarin 
Warfarin Status Risk of ischemic stroke per day Events/Days of observation (rate) 
 1-77 days 78-329 days ≥330 days 
Observed rates    
No 5/7301 6/15360 4/24112 
 (0.068%) (0.039%) (0.017%) 
Yes 0/1152 0/6830 1/28325 
 (0.00%) (0.00%) (0.0035%) 
Hazard ratio 0.00 0.00 0.21 
Rates used in prediction model*  
No 0.068% 0.039% 0.017% 
Yes 0.0075%§ 0.0043%§ 0.0018%§ 
*The Cox proportional hazard model provided a Warfarin Hazard Ratio for recurrent 
intracranial hemorrhage of 5.57 (95% CI 1.80-17.25) P=0.0029 and for ischemic stroke of 
0.11 (95% CI 0.0139-0.868) P=0.036. The rates used in the prediction model were based on 
these hazard ratios as follows: †Observed rate on warfarin/5.57, ‡Observed rate without 
warfarin x 5.57, §Observed rate without warfarin x 0.11. The remaining proposed rates are 
those actually observed 
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The data presented in the paper, including the observed and predicted rates 
presented in table 1, show a relatively higher initial rate of recurrent ICH 
compared to later periods in the group that did not restart warfarin, and this 
initial rate is multiplied by a factor of 5 when warfarin is restarted after ICH. 
With time, the risk of recurrent ICH in the group that did not restart warfarin 
decreased successively, and even though restarting warfarin at any time would 
still increase the risk by a factor of 5; the declining rates of bleeding in the 
absence of warfarin meant that the risks of recurrent bleeding with warfarin also 
declined. The rates decline rapidly in the first 10 weeks from the index ICH 
event.  
Similarly, data show a much higher initial rate of thromboembolic events 
immediately after the ICH, declining with time after the index event. Adding 
warfarin at any time reduced the risk of a new ischemic event, but unlike 
recurrent ICH, the rates of ischemic events continued to be relatively high with 
time as shown in figure 6.  
To determine the optimal timing of resumption of warfarin after an ICH we 
looked at the “total risk” which is the cumulative risk of recurrent ICH, and 
ischemic events before and after warfarin resumption through the intended 
treatment period. Given that the overall survival in our material is 4.5 years, we 
looked at the “total risk” in different treatment periods or horizons. This total risk 
gives similar weight to a recurrent ICH and ischemic event.  Even though the 
point of intersection between the curve for recurrent ICH and ischemic event 
varied according to the treatment period, the “total” risk remained constant, and 
showed a much higher initial total risk if warfarin is started early after ICH, 
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driven by the high incidence of recurrent ICH, and similarly a high total risk if 
warfarin is restarted late, driven by the cumulative risk of ischemic events 
(Figure 6). The optimal period of resumption of warfarin, which carried the 
lowest “total risk” for the combined recurrent ICH and ischemic stroke before 
and after the time of resumption appears to be between 10 to 30 weeks after the 
index warfarin-related ICH.  
Similar results were obtained when the analysis was not restricted by the 
inclusion of patients with previous stroke or cardiac indication for 
anticoagulation.  
 
  
Figure 6: Risk of recurrent ICH and ischemic stroke 
according to VKA resumption time 
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STUDY II 
 
Baseline characteristics 
A total of 144 patients were included in the study at the three centers but 9 were 
excluded from further analysis because their CT scans were not available for 
calculation of the ICeH volume, leaving 135 patients from whom data were 
included in the statistical analysis. All of the Dutch patients (n=65) and most of 
the Swedish patients (35 of 40) received treatment with PCC, while all of the 
Canadian patients (n=30) and some Swedish patients (5 of 40) received plasma. 
There were some imbalances in the prevalence of prognostic factors between the 
plasma-treated group and the PCC-treated group, including larger ICeH 
hematoma (64.5 cm3 vs. 36.0 cm3, p=0.021)(figure 7), more frequent 
intraventricular extension of the ICeH hematoma (60% vs. 32%, p=0.004), more 
use of antiplatelet agents together with anticoagulants (26% vs. 7%, p=0.008) 
and higher incidence of diabetes (40% vs. 18%, p=0.008) in the plasma-treated 
group. The median time to administration was also – as expected – significantly 
longer in the plasma group compared to the PCC group (15.5hrs vs. 4hrs, 
p<0.001). No significant differences were found between the groups regarding 
age, sex, cause of ICeH (traumatic or spontaneous), INR on presentation, 
bleeding localization, surgical evacuation of the hematoma, or INR on 
presentation (2.9 vs. 3.0) .The characteristics of the included patients are shown 
in table 1 of the original paper.  
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When comparing the Swedish and Dutch centers, where most of the patients 
were treated with PCC, there was no significant difference in the initial 
hematoma volume (31.1 cm3 vs. 38.6 cm3, p=0.39) nor in the presenting INR 
(2.8 and 3.1). 
The Pearson’s r coefficient for the correlations between the measurements from 
the two radiologists was 0.99 indicating very similar results by both radiologists 
for the measurement of the ICeH volume.  
Figure 7: Distribution of intracerebral hematoma volume 
according to reversal group. 
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The distribution of INR on presentation is shown in figure 8. Sixty-two patients 
(47%) had therapeutic INR on presentation, and exactly the same number of 
patients had supratherapeutic INR, whereas the remaining patients (n=10, 6%) 
had subtherapeutic INR on presentation.  
 
 
 
VKA reversal 
Four different types of PCC were used in the study, all of which were 4-factor 
PCC. All Dutch patients received Cofact® (Sanquin BV, n=65 [65%]). The 
Swedish patients received either Ocplex® (also called Octaplex®, Octapharma, 
Figure 8:Distribution of initial INR according to reversal group 
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n=25 [25%]), Prothromplex-T (Baxter, n=6 [6%]), or Beriplex (CSL Behring, 
n=1 [1%]). In three cases (3%) the type of PCC given was not documented. The 
patients received a median dose of 1750 IU, corresponding to a median of 22.5 
IU/kg (interquartile range [IQR] 20–26).  Seventy-one patients (71%) received 
an “adequate” dose of PCC, defined as a dose corresponding to at least 75% of 
the dose calculated to be sufficient to correct the initial INR to a level of 1.5 or 
less. 
The plasma-treated group (all 30 Canadian patients and 5 of the Swedish 
patients) received a median dose of 4 units (IQR 3-6 units), corresponding to 
about 1000ml, with a wide variation from 1 unit up to 20 units of plasma.  
In addition to plasma or PCC, patients with major bleeding were usually given 5-
10mg of vitamin K intravenously.  
 
Effect of plasma and PCC on mortality. 
We decided to consider the 30-day all-cause mortality for the comparison of the 
effect of plasma and PCC on the outcome of ICeH. Of all the patients included in 
the study, 51 (38%) died during the first month. When looking at the two 
treatment groups, 19 (54%) of all patients who received plasma died within the 
first month compared to 32(32%) in the PCC group. These data indicate a strong 
effect of PCC on the reduction of 30-day mortality after warfarin related ICeH, 
with a statistically significant crude OR of 0.40 (95% CI, 0.18–0.87, p=0. 021).  
Because of the differences between the two treatment groups in the prognostic 
variables at baseline, a multivariate analysis was done using step-wise logistic 
regression. Three variables had a significant impact on the mortality of the 
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patients, the strongest of which was the volume of the ICeH (p<0.001), then the 
bleeding localization (p=0.0049) and then age (p=0.044). Adjusting for these 
three variables, and especially for the hematoma volume, in the regression model 
reduced the beneficial effect of PCC on mortality as compared to plasma to an 
OR of 0.49 (95% CI, 0.19 to 1.24), which was not statistically significant with p-
value 0.13 (Figure 9). Further adjustment for other prognostic variables, and 
even when taking into consideration the difference in the time to administration 
between the PCC and plasma group, did not impact the results significantly. 
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STUDY III 
 
Baseline characteristics 
Two hundred and ten patients were included during the study period, however 50 
patients were later excluded from further analysis (in 35 cases PCC was given 
for other indication than VKA reversal, and in 15 patients no clear 
documentation of treatment with PCC, despite recommendation for such 
treatment, was found in the medical notes). The demographics of the remaining 
0.
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00
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Days after ICeH
Reversal = Plasma Reversal = PCC
Survivor functions
adjusted for hematoma volume
Figure 9: The 30-day mortality after warfarin -related intracerebral 
hemorrhage without and with adjustment for hematoma volume 
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160 patients are shown in table 1 in the original paper. Even though the study 
was planned to include patients from centers in two thirds of the country, about 
two thirds of the actually included patients (62.5%) were at three tertiary referral 
hospitals in Stockholm. The most common indication for VKA treatment in this 
study, as in the previous two, was AF (n=73, 46%), and the median age was 75 
years (IQR 65–80). Two thirds of the patients were males (n=109, 68%) and the 
median weight was 76kg (IQR 70-85).  
The initial INR in 95 patients (59.4%) in the study was supratherapeutic, 57 
(35.7%) had therapeutic INR and the remaining 7 patients (4.4%) had 
subtherapeutic INR values. The distribution of INR according to the indication 
for reversal is presented in table 2.  
Table 2: Distribution of INR before and after treatment according to PCC 
indication  
 All patients* Bleeding Emergency surgery* 
 N=160 N=116 N=44 
Initial INR, median (IQR) 3.5 (2.6-5.4) 3.5 (2.6-5.4) 3.6 (2.8-5.1) 
Sub-therapeutic (%) 7 (4.4) 2 (1.7) 5 (11.4) 
Therapeutic (%) 57 (35.7) 47 (40.5) 10 (22.7) 
Supra-therapeutic (%) 95 (59.4) 67 (57.8) 28 (63.6) 
INR after PCC, median (IQR) 1.4 (1.2-1.6) 1.3 (1.2-1.6) 1.5 (1.3-1.7) 
INR <1.5 91 (56.9) 72 (62.1) 19 (43.2) 
INR 1.5-1.9 45 (28.1) 27 (23.3) 18 (40.1) 
INR >1.9 12 (7.5) 8 (6.9) 4 (9.1) 
No INR available 12 (7.5) 9 (7.8) 3 (6.8) 
PCC – prothrombin complex concentrate; INR – International Normalized Ratio. IQR–interquartile range 
* Initial INR not available for one patient in the emergency surgery group 
  
  67 
The indication for treatment with PCC in most of the cases was reversal of VKA 
effect because of a bleeding event (n=116, 73%), while the remaining patients 
(n=44, 28%) received PCC for urgent VKA reversal preoperatively. The most 
common type of bleeding treated with PCC was ICH (n=59, 37%) followed by 
GI bleeding (n=21, 13%). In addition to PCC, 74% of the patients received 
treatment with vitamin K intravenously at doses between 2-10mg.  
 
Prothrombin complex concentrates  
Different types of PCC were used in the study, depending on the local 
availability, but most of the patients (96.3%) received either Prothromplex 
(Baxter), or Ocplex (elsewhere called Octaplex, Octapharma) or Beriplex (CSL 
Behring). Doses ranged from 8 IU/kg (600IU) to 63 IU/kg (3500IU), the lowest 
was given to a patient with ICH presenting with an INR of 1.5, and the highest to 
another ICH patient with INR 6.3, and resulting in lowering of the INR to 1.2 
and 1.7 respectively. The median dose of PCC given in the study was 1800IU 
(1200–2000IU) corresponding to 24 IU/kg (IQR 18–29). Most of the patients 
(n=118, 74%) received vitamin K and a third (n=55) received plasma in addition 
to PCC.  
 
Safety assessment 
Two investigators independently reviewed the charts of all 160 patients, but 2 
patients were excluded from further analysis because no discharge notes were 
available to allow for complete safety assessment. In the remaining 158 patients, 
the two investigators agreed on the absence of thromboembolic events in 149 
cases, and on the occurrence of thromboembolic events in 9 cases, with a 
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“possible” relationship to PCC treatment. In three of these 9 patients, the initial 
clinical suspicion of a thromboembolic event (1 stroke and 2 pulmonary 
embolisms) was not objectively verified leaving only 6 cases of objectively 
verified thromboembolic events occurring within a week after PCC 
administration where a possible causal relationship was identified in the study 
(table 3). These included 5 arterial events (3 with stroke, 1 myocardial infarction 
[MI], and 1 systemic embolism to the spleen) and 1 DVT. Two of the patients 
with stroke had AF as VKA indication, and the third stroke patient was on 
warfarin due to a PHV.  
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In two cases, the two investigators disagreed on whether the patient had suffered 
a thromboembolic event or not, these two cases were resolved after review by a 
third independent investigator. Overall the agreement between the two 
investigators was very good with a kappa coefficient of inter-observer agreement 
of 0.88 (95% CI 0.72- 1.04). 
 
Mortality 
Ten patients died within the first week after treatment with PCC; the details of 
these patients are available in table 4. Seven patients (6.1%) had VKA-related 
bleeding (5 of these patients had warfarin-related ICH on admission, one had 
retroperitoneal bleeding, one had post-operative bleeding) and 3 (6.7%) were in 
the emergency surgery group. Thromboembolism was judged to be a 
contributing factor to the death of one patient (patient 10, table 4) who presented 
initially with bacterial meningitis and high INR that was reversed with PCC 
before a lumbar puncture; the patient developed an ischemic stroke 2 days after 
PCC administration and the final cause of death as recorded in the death 
certificate was a combination of infectious meningitis and ischemic stroke. 
  
  71 
 
Table 4: Causes of death within the first week after PCC treatment 
Patient Age Sex Indication 
for VKA  
Indication for 
reversal 
Death after 
PCC (d) 
Death Cause 
1 87 F PHV ICH 5 ICH 
2 83 F PHV Surgical bleeding 4 Pneumonia, 
heart failure 
3 80 F VTE Emergency 
surgery 
7 Septicemia 
4 81 M AF Retroperitoneal 
bleeding 
0 Hypovolemia  
5 74 M PHV ICH 0 ICH 
6 61 F PHV ICH 1 ICH 
7 79 F Stroke ICH 1 ICH 
8 79 M AF Emergency 
surgery 
2 Septicemia, 
organ failure 
9 85 M PHV ICH 0 ICH 
10 83 M AF Emergency 
surgery 
5 Septicemia, 
stroke 
 
 
Assessment of efficacy 
Clinical assessment of the outcome of the patients, in addition to the effect on the 
INR was used in the efficacy assessment. Overall, complete data for efficacy 
evaluation was available for 156 patients; 146(91%) of whom were adjudicated 
by the two investigators in the study to have a good effect of given PCC.  
The effect of PCC was adjudicated as poor in 4(3%) patients, all of whom had 
ICH on admission and after receiving PCC in doses of 20-31 IU/kg, the INR was 
reversed to between 1.2-1.5 in all 4 cases. Three of these cases were also given 
vitamin K and one was given plasma. The outcome of the bleeding was fatal in 3 
of the 4 patients shortly after admission. 
For 6 patients the effect of PCC was adjudicated as moderate (4 with ICH and 2 
with GI bleeding); only 3 of these 6 patients attained an INR of 1.5 or lower after 
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PCC, and the PCC dose given to 2 of these patients was estimated as suboptimal 
for full reversal.  
There was no significant difference between the post-PCC treatment INR of 
patients with ICH and good effect of PCC versus those with moderate and poor 
effect of PCC (1.3 vs. 1.35, P=0.423). The details of the patients with suboptimal 
effect of PCC are shown in table 5. 
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STUDY IV  
 
Baseline demographics 
A total of 1034 patients, who suffered a centrally adjudicated major bleeding 
event in the 5 phase III trials on dabigatran, met the inclusion criteria for our 
study. Some of these patients suffered more than one major bleeding event, so 
the total number of bleeding events in the study (1121) was higher. The number 
of patients randomized in the 5 phase III trials and the demographics of the 
subgroup included in our study are summarized in tables 1 and 2 in the original 
paper.  
Altogether, we had data on 262 major bleeding events in 6,015 patients treated 
with dabigatran 110mg bid, 365 major bleeds in 10,740 patients treated with 
dabigatran 150mg bid, and 408 major bleeding events in 10,002 patients treated 
with warfarin. Patients who had major bleeding event on dabigatran were 
significantly older (mean age in the dabigatran 110mg bid was 75.9, in the 
dabigatran 150mg bid 75.1, and in the warfarin group 71.7, dabigatran vs. 
warfarin p <0.0001), had more impaired renal function (mean creatinine 
clearance in the dabigatran 110mg BID was 51, in the dabigatran 150mg bid 55, 
and in the warfarin group 62 mL/min, dabigatran vs. warfarin p <0.0001) and 
had more frequent use of aspirin (dabigatran 110mg bid 35.1%, dabigatran 
150mg bid 27.4%, and warfarin group 24.8%, dabigatran vs. warfarin p <0.038) 
and of NSAIDs (dabigatran 110mg bid 16.4%, dabigatran 150mg bid 12.1%, and 
warfarin group 8.3%, dabigatran vs. warfarin p <0.006). 
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Transfusion of blood products 
About one third of the patients in our study (n=365, 33%) did not receive blood 
transfusion or any other blood products, (dabigatran 110 mg – 100 of 293 events 
[34%], dabigatran 150 mg – 126 of 403 events [31%], warfarin – 139 of 425 
events [33%]). Transfusion of red cells only (ie, without any other blood 
products, coagulation factors, vitamin K, or local hemostatic intervention), was 
given to a significantly larger number of patients in the dabigatran arm (35%; 
dabigatran 110 mg – 137 of 293 bleeds [47%], dabigatran 150 mg – 173 of 403 
bleeds [43%], warfarin – 85 of 425 bleeds [20%]), however, the difference in the 
median number of units transfused per patient in the three arms was not 
statistically significant. The details and comparisons are summarized in table 3 in 
the publication.  
When looking at the hemoglobin levels taken during different time points in the 
RE-LY study, we noticed a drop in hemoglobin for all patients in the studies, 
regardless the type of anticoagulation and regardless if they had a bleeding event. 
In patients who suffered a major bleeding event, the drop of hemoglobin from 
the time of randomization until the bleeding event was significantly larger in the 
dabigatran arm (dabigatran, 38.0 g/L, warfarin, 30.7 g/L; P=0.02). Similarly, in 
patients who did not suffer any bleeding event, the drop in hemoglobin during 12 
months was significantly larger in both dabigatran groups compared to the 
warfarin treated group (0.6g/L [0.14–1.06] greater for dabigatran 110mg bid, 
p=0.011, and 1.1 g/L [0.63–1.57] greater for the dabigatran 150mg bid, 
p<0.0001). 
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Transfusion of hemostatic agents 
Data were available on the transfusion of plasma, vitamin K, factor concentrates, 
cryoprecipitate, or platelets from the CRFs and the event reports, mainly from 
the RE-LY trial. Most of the patients with major bleeding events were either 
managed conservatively without any transfusion or only transfused with red 
cells. Consequently, only a small fraction of the major bleeding events were 
managed with transfusion of hemostatic agents. 
The proportion of patients transfused with plasma was significantly smaller in 
the dabigatran groups (61[17.8%] patients in the dabigatran 110mg, 86 [21.6%] 
patients in the dabigatran 150mg versus 127 [30.2%] than in the warfarin arm (p 
value significant for all comparisons with warfarin) 
There was a low frequency of utilization of other factor concentrates, 
cryoprecipitate, or platelets without a significant difference between the study 
drugs. There were very few patients who received treatment with rVIIa or PCC 
for dabigatran- or warfarin-associated bleeding, and none of the patients in all 
the studies received APCC. 
 
Other treatment modalities 
Vitamin K was mainly given to warfarin- related major bleeding events in the 
phase III trials: in 59 bleeds (14%) it was given as the only treatment while in 73 
bleeds (17%) it was given in conjunction with other hemostatic agents. Fewer 
patients in the dabigatran 110mg or 150mg groups received vitamin K in the 
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event of a major bleeding, corresponding to 18 (2.6%) and 39 bleeds (5.6%) 
respectively. 
Hemodialysis was used in one patient in the RE-LY trial, who was on dabigatran 
treatment, and who developed moderate renal impairment with dabigatran 
accumulation before major surgery (coronary artery bypass grafting), resulting in 
massive postoperative bleeding with transfusions of blood, plasma, platelets, 
cryoprecipitate, 5 doses of rFVIIa, and fibrin glue without successful control of 
the bleeding despite this massive transfusion. After 6 hours of dialysis, the 
thrombin time was shortened from 128 to 65 seconds and the bleeding was 
controlled.  
 
Hospitalization and discharge destinations 
Data on hospitalization and the discharge destination were available mainly for 
patients in the RE-LY trial. The proportion of patients requiring hospitalization 
after a major bleeding event was comparable in all the three treatment groups 
(150 [43.9%] in the dabigatran 110mg group, 199 [49.9%] in the dabigatran 
150mg group and 198 [47.0%] in the warfarin group, p value not significant for 
all between-groups comparisons). Similarly, there were no significant 
differences in the between-groups comparisons of the length of hospitalization 
(mean days [SD]; 7.0 [7.0] for the dabigatran 110mg group, 7.0 [8.0] for the 
dabigatran 150mg and 7.0 [8.0] for the warfarin group), or of the number of 
nights in the step-down units (mean days [SD]; 0.8 [2.1] for the dabigatran 
110mg group, 1.0 [2.7] for the dabigatran 150mg and 1.0 [2.7] for the warfarin 
group). However, the length of stay in the intensive care unit was significantly 
shorter for both dabigatran treatment groups than that of warfarin (mean days 
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[SD]; 1.2 [3.3] for the dabigatran 110mg group, 2.5 [6.1] for the dabigatran 
150mg and 3.2 [7.0] for the warfarin group, p-value significant for all 
comparisons of dabigatran with warfarin). There was also a trend toward lower 
number of patients with bleeding events requiring surgery or resulting in death in 
the dabigatran groups (56 [16.4%] in the dabigatran 110mg group, 76 [19.0%] in 
the dabigatran 150mg group and 94 [22.3%] in the warfarin group, p-value for 
comparison between dabigatran and warfarin treatment groups=0.06) 
Information on discharge destination was available for 710(52%) of all patients 
in the RE-LY trial who required hospitalization after a major bleeding event. The 
destination was defined in the medical records as one of three categories: home, 
long-term facility, or other hospital. The details of the number and proportion of 
patients discharged to these three destinations are summarized in table 4 of the 
publication; there was no significant difference in the proportion of patients 
discharged to the different destinations in any of the comparisons between the 
treatment groups.  
 
Disability 
Data on the disability after ICH, measured with mRS both at admission and upon 
discharge, was available for 78 (55%) patients with ICH. At presentation, the 
dabigatran 150mg group had a significantly higher mRS than the warfarin group 
(median [IQR]; 6[1] for the dabigatran 150mg, 5[3] for the warfarin group, 
p=0.03). However mRS at follow-up and the differences between the initial and 
the final mRS for all the three treatment groups were not significant (see table 4 
in the published study). 
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Mortality after major bleeding 
Mortality after the first major bleeding event, pooled from all the 5 phase III 
trials, was significantly lower at day 7 in the combined dabigatran treatment 
group as compared to warfarin (5.3% vs. 8.4% respectively, p=0.045). At 30 
days, the crude rates showed a strong trend to lower mortality in the dabigatran 
group (9.1% vs. 13.0% p=0.057). Similarly, the Kaplan-Meier curves showed a 
strong trend to better survival in the combined dabigatran treatment group 
(p=0.052) (fig 10).  
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Figure 10. Kaplan-Meier curve for the 30-day mortality after a major bleeding 
event. 
Because the baseline characteristics of the dabigatran and the warfarin-treated 
groups were different at baseline, adjustment was done using logistic regression. 
After adjustment for age, sex, body weight, renal function at the time of the 
bleed, and additional antithrombotic therapy, the OR for the 30-day all-cause 
mortality in the dabigatran treated group was 0.66 (95% CI, 0.44–1.00; 
P=0.051). When stratified by dabigatran dose, the adjusted ORs were 0.65 (95% 
CI, 0.38–1.11) and 0.68 (95% CI, 0.42–1.08) for the 110mg and the 150mg 
respectively. 
There was a significant difference in the occurrence of concomitant cancer 
between the AF (RE-LY) trial and the 4 combined VTE trials (5% versus 36%; 
P=0.003). Therefore, a further analysis was done for the RE-LY study alone. 
Corresponding adjusted OR for 30-day mortality in RE-LY for the combined 
dabigatran treatment doses was 0.56 (95% CI, 0.36–0.86; P=0.009), for 
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dabigatran 150 mg it was 0.52 (95% CI, 0.31–0.88), and for dabigatran 110 mg it 
was 0.60 (95% CI, 0.35– 1.03) indicating mortality benefits in the combined 
dabigatran groups and for the 150mg dose compared to warfarin.  
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4  DISCUSSION 
 
METHODOLOGICAL ISSUES 
 
General design considerations 
Study I and II were conducted with a retrospective design, while in Study III the 
information was collected prospectively. Study IV is an ad-hoc analysis, ie 
retrospective analysis of data collected prospectively to answer a question 
(outcome of bleeding) different from the primary one (efficacy of dabigatran 
versus warfarin). Randomized controlled trials are the golden standard in study 
design because of their ability to control for known and unknown confounders, 
and since patients are followed prospectively, they can also minimize the risk for 
any spurious causality and bias. However, it is sometimes not feasible to use 
RCT design to address a certain question, either because such a design would be 
ethically questionable (e.g. using an RCT to answer the question in Study III), or 
because the RCT would be costly and run for many years when the outcome is a 
rare event (e.g. using RCT instead of retrospective design for Study I and II). In 
fact, an RCT with similar design to Study II has been running since 2009225, but 
according to personal communication with the principle investigator of the 
study, “recruitment has been slow”. In such situations, retrospective studies or 
prospective non-randomized trials can be an alternative. Including consecutive 
patients improves the study internal validity in this case, as we did in Study I and 
II. Having a control arm allows calculating the relative risk or OR depending on 
the study design and gives additional information, but even a control arm is 
sometimes not possible (e.g. Study III as discussed in individual study results 
below). Considering the questions we wanted to answer, the design chosen for 
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each of the four studies can be considered the best for limiting the time frame 
and with the resources available.  
 
Internal validity 
 
a. Selection bias 
Selection bias occurs when individuals selected for inclusion in a study, or their 
likelihood of completing the study (i.e subject retention in the study) leads to 
results that are different from those obtained if the entire population at risk 
would have been included. Such bias might cause the exposure-outcome 
distribution in the sample selected to be different from that in the general 
population at risk, leading to spurious estimate of the exposure-outcome 
relationship.  
In Study I and II, a certain “selection bias” might have been introduced by 
including patients from tertiary referral centers only, where more advanced and 
skilled management possibilities exist, leading to a possible selection of more 
complicated cases with ICH which are usually referred to highly experienced 
centers with possibilities of neurosurgical intervention. However, most of the 
services provided in these four hospitals are actually based on the catchment area 
and to a much lesser extent on the severity of the condition of the patient. In 
addition, we endeavored to identify and include consecutive cases of VKA-
related ICH. The ICD-10 codes were used to identify the population with ICH 
during the study period in the three hospitals in Sweden and Canada, and these 
journals were then scrutinized to identify VKA-related ICH according to a strict 
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definition. This system is based on the assumption that cases of ICH are 
correctly coded for with the ICD-10 system. Since all cases of ICH are managed 
as in-patients, it is unlikely that cases will be missed due to incorrect ICD coding 
at the emergency unit or the outpatient clinic, and any cases that might be 
wrongly coded would only result in a random rather than a systemic error.  
In Study III, our intention was to include patients consecutively, however, this 
could not be achieved as an unknown number of cases were missed by the 
hematologist on-call. This process occurred randomly without any specific 
pattern, and is therefore unlikely to cause a systematic error. On the other hand, 
it is also possible that a consulting physician would contact the coagulation 
center at Karolinska University Hospital to discuss more complicated cases, with 
fragile bleeding-thromboembolism balance, and higher risk of thromboembolism 
regardless of treatment administered. Moreover, there is an “indication bias” in 
this group; patients receive PCC because they are on warfarin due to an 
increased risk of thromboembolism, and they are either bleeding or in need of 
emergency surgery, both of which inherently increase the risk of 
thromboembolism, i.e. PCC is given to a group that already has an increased risk 
of the outcome of interest (thromboembolism in this case). The two last 
mentioned factors could potentially result in an “overestimation” of the risk of 
thromboembolic events after PCC administration; however, such overestimation 
is clinically relevant since PCC is usually given to similar patient groups. The 
rates we found in our study were comparable to other published reports226-228. 
The optimal design to measure the PCC-attributable risk increase would be to 
administer PCC to healthy patients given warfarin just to assess the safety of 
reversal with PCC, a design that is neither ethical nor possible to do on a large 
scale, even though a study with comparable design was published in a 
prestigious journal recently196. The method we used reflects the real world 
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scenario in a better way. When assessing the safety of a treatment, it might be 
also be argued that it is preferable to choose a design that would optimize the 
chance of detecting adverse events (even if it results in an overestimation of the 
outcome of interest) than one that underestimates the risks associated with the 
treatment. 
In Study IV, the source population of the five phase III trials was selected 
according to rigorous inclusion and exclusion criteria and, as in many other 
RCTs, there is always a risk of the study sample being different from the larger 
patient population by recruiting generally healthier, more compliant individuals 
thereby introducing some Healthy Worker Effect. This is a known issue with 
RCTs that is difficult to overcome. 
When it comes to the issue of subject retention, this is more important to 
consider in prospective trials. In Study III we had two patients of the 160 
included that had to be excluded from the safety analysis because discharge 
notes were not available, however, there was no mentioning of any 
thromboembolic events in the available medical notes. We had complete one-
week follow-up of the remaining 158 patients, enabling us to assess the 
occurrence of any thromboembolic event during the pre-specified time frame of 
1 week after PCC treatment. A small number of patients died before completing 
the first week of follow-up, but we had access to the cause of death as reported in 
the death certificate. Study IV included patients from one open-label RCT (RE-
LY) and 4 double blinded RCTs (RE-COVER, RE-COVER II, RE-MEDY and 
RE-SONATE). Although the phase III studies had some drop outs, more in the 
double blinded trials than the open label as expected due to the complexity of the 
protocols of blinded studies, this did not affect our subgroup analysis. Our 
starting point was all patients who developed a major bleeding event on 
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treatment, and since such bleeds are generally treated as in-patients, and 
followed closely as part of the original study, with transfusions of blood products 
recorded according to specific forms, it is unlikely that subject retention bias 
affected the results of our study.  
 
b. Confounders 
One important co-variant that we were unable to adjust for in Study II is the 
Glasgow Coma Scale (GCS). The GCS at presentation was related to the 
mortality of ICH in a number of studies229,230. Our data on the important 
prognostic covariates were collected retrospectively from medical records. In 
many cases the admitting physician did not record the GCS and in some cases an 
alternative system called the RLS-85 (Reaction Level Scale), popular in 
Scandinavia231, was used instead to document the level of consciousness of the 
patient. This system cannot be translated directly to GCS. In most of the cases 
where GCS was not recorded, the information available in the medical records 
was insufficient to calculate the GCS. More importantly, the volume of the 
ICeH, which we have adjusted for in all patients, is a better predictor of the 30-
day mortality than GCS232.  
 
c. Assessment of exposure variables 
In Study I and II, we examined the medical records and hospital medications to 
ensure that the patients were receiving anticoagulation with VKA at the time of 
the bleeding. We also reviewed the laboratory results and included only patients 
with INR over 1.5 to ensure that there was an antihemostatic effect of VKA at 
  87 
the time of the event. All ICHs had to be objectively verified by imaging 
(Computerized Tomography or Magnetic Resonance Imaging). Laboratory 
parameters and other covariates were collected from records at the time of the 
bleeding event. Both hospital medication charts and medical notes were used to 
confirm the dose and administration of PCC or plasma. Time from onset of 
symptoms to transfusion of PCC or plasma was calculated from the information 
available in the medical records, introducing some element of uncertainty 
depending on the accuracy of this documentation. There is of course a question 
of the quality and representativeness of the data registered in the medical 
journals, which is always a limitation in retrospective study. We tried to confirm 
the data collected in the study by checking the same information from different 
sources (e.g. medical notes, laboratory results, hospital medication notes, reports 
of diagnostic imaging etc). When the time for onset of symptoms was recorded 
as a range we used the mid-point in our estimation of the treatment delay. 
For Study III, the data was collected prospectively, hospital medication charts 
were examined to confirm that the patient actually received PCC and to verify 
the dose given. We also reviewed the nursing notes regarding the administration 
of PCC and the INR before and after the stated administration of PCC to make 
sure that the patient received the treatment. In Study IV, information on the study 
individuals was available from the 5 phase III trials according to pre-specified 
CRFs and collected in the study databases. The RE-LY trial databases were 
maintained both by the sponsor (Boehringer Ingelheim) and by the trial 
management (Population Health Research Institute) in different formats. We had 
two independent investigators extract the information from the serious adverse 
events narratives and the bleeding event narratives, any discrepancy was re-
evaluated and the final data set was further checked against the study databases. 
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d. Assessment of outcome variables 
The outcome variables in Study I, II and IV were chosen as hard endpoints and 
were objectively verified. Recurrent ICH or ischemic events were based on the 
development of new neurological symptoms but also a radiological verification 
was required in study I. Since this study was done retrospectively, there was no 
protocol in place to determine the point of VKA resumption or recommend 
radiological investigations at specific time points to assess for asymptomatic 
recurrent ICH or ischemic stroke. The design we used mimics, however, closely 
the every day clinical setting and could be considered as strength rather than a 
limitation of the study. In Study II and IV, another hard end point (30-day all-
cause mortality) was used and this data was available for all the patients included 
in the study. The rationale for using this rather than cause-specific mortality has 
been discussed previously in the methods section. The primary outcome in Study 
III was safety, and for that the occurrence of a thromboembolic event had to be 
objectively verified. In the efficacy assessment two investigators independently 
reviewed the medical records according to pre-defined criteria to increase the 
level of objectiveness. 
In summary, we tried to use as objective assessment as possible for both 
exposure and outcome variables to improve the data quality and the internal 
validity of the study 
 
External validity 
External validity of a study refers to the generalizability of the results of the 
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study. A good internal validity (which has been discussed previously) is a 
requirement for external validity. Other important aspects of a study that 
influence its external validity are if the individuals in the study, the time period 
of the study, the settings, and the places where the study was conducted are 
similar to the group(s) we want to generalize the results to. All the four studies 
included patients from several centers (“places”), and inclusion was not limited 
to specific age groups, sex, race or other individual factors. We have even 
included patients with a spectrum of VKA indications (SPAF and VTE in all 
four studies, PHV and previous stroke in study I, II, III, since dabigatran in 
Study IV has not been approved for PHV). In the studies on ICH we included 
both spontaneous and traumatic (although not severe multitrauma where ICH has 
a different natural course), deep and lobar ICeH, all subsets of ICH in Study I 
(ICeH, SAH, SDH) and with INR in the subtherapeutic (1.5-1.9), therapeutic 
(usually 2.0-3.0) and supraterapeutic range. The setting of VKA reversal in 
Study III included both patients with bleeding and those requiring emergency 
surgery and used several types of PCC as a reversal agent. Study IV was not 
limited by a specific bleeding localization or cause, and the bleeding was 
managed in different types of hospitals, primary to tertiary center. The rigorous 
inclusion and exclusion criteria in the 5 phase III trials may limit the 
generalizability both of the results of all the phase III trials and of our subgroup 
analyses. The four studies in this thesis included patients during different periods 
within the last 10 years, during which the indications of VKA, the diagnosis and 
management of major bleeding events, and the use of plasma or PCC have not 
changed much from current ones. These factors altogether imply that our studies 
have good external validity. 
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DISCUSSION OF THE INDIVIDUAL PAPERS 
 
Study I: Restarting warfarin after ICH 
 
Main results 
In this study, we reported a risk-benefit analysis of the optimal timing for 
resumption of anticoagulation after warfarin-associated ICH. The multicenter 
design, the relatively large number of included patients and of events in the 
study, and the modeling of the risk of bleeding and ischemic events before and 
after anticoagulation allows us to provide a better estimate of the optimal 
resumption interval. In contrast to previous studies, our data have shown that the 
optimal timing of resumption is between 10-30 weeks after the warfarin-related 
ICH. The span of 20 weeks allows for individualization of the exact point of 
anticoagulation resumption depending on the risk of recurrent bleeding or 
thromboembolism. According to this discussion, patients with a higher risk of 
recurrent bleeding, e.g. those with SDH, can be restarted later in this interval and 
those with higher risk of thromboembolism, e.g. PHV can be restarted around 
week 10 after ICH. This seemingly long delay of at least 10 weeks until 
resumption of anticoagulation might seem prohibitive for a patient with PHV. 
Taken in perspective, the risk of thromboembolism without anticoagulation has 
been estimated at 8.6% per year without any anticoagulation66, which would 
correspond to 1.7% during 10 weeks. This might be higher after a bleed and 
might be reduced somewhat by giving low-dose aspirin in the meantime, which 
does not appear to increase the risk of recurrent ICH. More importantly, with the 
risk of recurrent ICH in case of early resumption of VKA as high as 13%, it is 
not only much higher than the early risk of ischemic stroke but with a recurrence 
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the VKA will need to be discontinued again, probably for a much longer period. 
It should be investigated whether serial echocardiograms during the 10-week 
interval can identify small deposits of clots before they result in serious 
thromboembolism. 
 
Strength 
Our study comprises one of the largest published cohorts, where patients were 
included from several centers and with the longest follow-up of patients with 
warfarin-related ICH. Compared to other studies, we did not limit the inclusion 
to patients with PHV, but we included other high-risk groups, e.g. with cardiac 
indication for anticoagulation due to AF with additional risk factors for stroke, 
patients with myocardial infarction developing intramural thrombus, and patients 
who had a previous stroke. We also had a larger number of events in our study 
that enabled us to build a model for the risk of recurrent ICH vs. the risk of 
ischemic stroke. In this model, we took into consideration for the first time the 
risk of bleeding and of ischemic events before and after the point of resumption 
of warfarin after an ICH and calculated a “total risk” of these combined events 
depending on the time of resumption and the treatment horizon with warfarin.  
 
Limitations 
The main limitation is the retrospective design without a study protocol to guide 
the exact timing of warfarin resumption and to optimize data collection. The 
point of resumption of VKA treatment was decided by the physician in charge 
and may have been biased by the fear for ischemic events or recurrent ICH. This 
is evident by the fact that patients with PHV were resumed on anticoagulation 
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earlier than those with other indications for anticoagulation. However, patients 
with previous stroke, who had an up to 28% risk of recurrent ischemic event in 
our material, were not restarted earlier than those without previous stroke, and 
patients with SDH, who in our material had a higher recurrence rate than other 
subtypes of ICH, were not restarted on VKA later or less frequently than patients 
with ICeH or SAH. Even though younger patients were restarted more often on 
VKA than older ones, we found no interaction between the risk of recurrence 
and age.  
Other limitations include the relatively low number of events in our study, even 
though we had larger number of events than all previously published studies. We 
also had a shorter follow-up of those who never resumed (median = 39 weeks) 
compared to those who resumed anticoagulation, but all the events of interest 
should have been captured by that follow-up duration.  
The best study design to answer the question of when to resume anticoagulation 
would have been an RCT. Such a design is not feasible due to the low rate of 
events that are eligible for inclusion in the study and the resulting long 
recruitment time and high cost. We had to include patients from three tertiary 
referral centers and to extend to a period of 5 years to reach the number of 
patients needed for the modeling in our study. Although we did not perform any 
formal power analysis, the size of our cohort and the inclusion from 3 centers 
over a 5-year period of an event that is relatively rare and carries a high mortality 
rate, together with the survival analysis makes our results the best available 
assessment of the optimal resumption time of warfarin after an ICH.  
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Comparison with other studies 
In one systematic review 120 patients with PHV as the indication for 
anticoagulation were pooled from 6 studies, all of which were of small size and 
had limited follow-up. The authors concluded that it was safe to resume 
anticoagulation after only 2 weeks from the ICH233. There were very few events 
in this analysis (2 recurrent ICH and 4 ischemic strokes). In another systematic 
review pooling data on 492 patients, the authors concluded that it was safe to 
restart anticoagulation within 72 hours, but this analysis had a number of 
methodological limitations, of which the main was the large number of single-
case reports with high risk of bias toward successful cases234.  
In one of the largest published cohorts of patients with warfarin-related ICH, no 
recurrent ICH was observed when 35 patients (out of 141 patients) resumed 
warfarin, which could well be explained be the short follow-up of only 30 
days218. In another cohort with 23 of 52 patients resuming anticoagulation, 3 
cases of recurrent ICH and 3 ischemic strokes were observed during a 43-month 
follow-up, but the low number of events makes it challenging to perform any 
statistical analysis or draw conclusions on the when to resume anticoagulation217.  
In another analysis, using a mathematical Markov model to assess the risk of 
recurrence, the authors suggested a difference in the rate of recurrence of deep 
hemispheric versus lobar types of ICeH, being higher in the latter, which led the 
authors to conclude that patients with the lobar subtype of ICeH should not 
resume anticoagulation235. This analysis is limited by the inclusion of only 
patients with AF having no additional risk factor for stroke. Other indications for 
VKA, e.g. high risk AF patients, patients with PHV or those with previous stroke 
have a much higher risk of ischemic stroke that may warrant resumption of 
anticoagulation even in patients with lobar bleeding localization. We were not 
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able to stratify our analysis of ICH according to the classification above because 
of insufficient number of events.  
 
Study II: Mortality in VKA-related ICeH treated with plasma or 4-
factor PCC 
 
Main findings: 
In this study, we are reporting results from the hitherto largest study comparing 
the 30-day mortality of warfarin-related ICeH treated with either plasma or 4-
factor PCC. The rationale of this study was that the more rapid reversal of the 
anticoagulant effect of warfarin by PCC (through supplementing vitamin K 
dependent factors and restoring normal hemostatic activity as evident by 
correction of prolonged INR), would lead to less expansion of the ICeH than in 
patients treated with plasma, which takes much longer to correct hemostasis. 
This difference would be mirrored by a lower 30-day mortality rate in the PCC 
group.  
We did observe significantly lower 30-day all-cause mortality in the PCC treated 
group (OR 0.4, p=0.021), however, much of that difference was due to 
differences in the baseline characteristics of patients in the two treatment groups, 
specifically, due to the larger volume of ICeH in the plasma group. Even though 
there were numerically fewer deaths in the PCC group, correcting for the 
imbalances in those characteristics caused the OR to increase to 0.49, eradicating 
the significant difference between the groups.  
One plausible explanation is that the main hematoma expansion and damage to 
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the brain tissue occurs early after the onset of the ICeH. The average time to 
administration of PCC in our study was 4 hours, and if the potentially fatal 
damage has already occurred during this initial period, subsequent administration 
of PCC will have minimal impact on the survival of patients. Even though the 
time to PCC administration was significantly shorter than plasma (mainly due to 
the need of plasma thawing, blood-group matching and infusion of a much larger 
volume), correction for this time difference did not influence the results of the 
study.  
 
Strength 
The main strength of the study is the relatively large number of patients 
(compared to previously published studies), the inclusion of consecutive cases 
and the multicenter design. Furthermore, we included information on 11 
potentially important prognostic covariates: age, sex, diabetes, concomitant 
antiplatelet therapy, cause of bleeding (provoked or spontaneous), INR before 
reversal, hematoma volume (ml) at presentation, bleeding localization, 
intraventricular hematoma expansion, time to administration of the reversal 
agent and surgical hematoma evacuation. There was also a very high agreement 
between the volume measurements of the ICeH by the two radiologists. The use 
of logistic regression allowed for the statistical correction of differences between 
basal characteristics that might influence the outcome.  
 
Limitations 
There are several limitations in our study. First, the data was collected 
retrospectively. The optimal design would have been a randomization of patients 
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with warfarin-related ICeH to either treatment with plasma or PCC. There are 
several problems with conducting such an RCT; first, there is an ethical issue 
that the randomization process itself might incur some further delay in the 
administration of the necessary reversal of anticoagulation, and such a delay by 
itself might lead to worsening of the patient’s outcome. Second, the annual rates 
of warfarin related ICeH are low and this would result in an unreasonably long 
study or a substantial increase in the cost to engage many centers to recruit the 
necessary number of patients.  
Another limitation is the sample size; the adjusted 30-day mortality analysis 
yielded an OR of 0.49 (95% CI, 0.19 to 1.24) with p-value 0.13. This result does 
not confirm any advantage of treatment with 4-factor PCC, yet the relatively 
small sample size has lead to somewhat wide confidence intervals and a benefit 
of treatment with 4-factor PCC cannot completely be ruled out, especially that a 
formal power analysis has not been done before conducting this study. However, 
we needed to review 5 years of data on patients with warfarin-related ICeH from 
four centers to obtain the sample size in this study as ICeH, a subset of ICH, is a 
rare event during treatment with warfarin and rates of VKA related ICH have 
been reported to be as low as 0.3%236.  
Another limitation of our study is that we did not have data on the GCS, which is 
correlated to the mortality in ICeH. We have, however, corrected for several 
other prognostic factors, including the most important one, namely ICeH 
volume.  
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Comparison with other studies 
Similar results were published in a Canadian study 194, where a median dose of 
1000 IU of PCC was administered to patients with warfarin-related ICH, 
including patients with ICeH, resulting in correction to INR below 1.5 in 72% of 
the cases within 1 hour. However, hematoma expansion was seen in 46% of the 
patients despite PCC and mortality was not reduced in comparison to historical 
data from patients receiving plasma for the reversal of warfarin-related ICeH.  
On the other hand, a study from New Zealand showed improved survival in 
patients with warfarin-related ICeH when using reversal protocols that included 
PCC237. This study had several limitations; first, the study did not directly 
compare PCC to plasma treatment, since most of the PCC treated patients (15 of 
23) received also plasma and the control arm of the study included patients who 
were treated with either plasma, vitamin K, or both or who received no treatment 
at all, which might improve the odds in the PCC treatment group. Second, even 
when plasma was used for reversal of warfarin in the study, the median dose of 
plasma given (2 units) is substantially lower than the dose needed for the 
adequate reversal of warfarin effect. Third, there were a number of differences in 
the baseline characteristics between the treatment groups, including the use of 
antiplatelet agents, which was not corrected for in the study analysis.  
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Study III: Thromboembolic safety and efficacy of PCC in the 
emergency reversal of warfarin coagulopathy 
 
Main findings 
The main focus in our study was on the safety of treatment with PCC assessed 
by the occurrence of arterial or venous thromboembolic events within a week the 
administration of PCC. We found in our study that there was a low rate of 
thromboembolic events following treatment with PCC of 3.8% (95% CI, 1.4-
8.0%), most of which were arterial events. When limiting the analysis to patients 
who had cardiac indication for VKA (i.e. AF or PHV) or who had previous 
stroke, the rate of stroke after PCC administration was even lower at 2.5%. It is 
important to recognize that patients who were anticoagulated with warfarin in 
this study had an underlying increased risk of thromboembolism without 
anticoagulation. Thus, the interruption of anticoagulation, as in the case of a 
serious bleeding or in surgery, would expose these patients to an increased risk 
of thromboembolism, even without PCC administration. In addition, the surgical 
intervention can activate coagulation and lead to an increased risk of VTE238 or 
myocardial infarction239. Any causality between PCC and the observed 
thromboembolic events should therefore be interpreted with caution.  
In terms of efficacy, most of the patients were adjudicated to have good effect of 
PCC and only 10 (6%) patients had poor to moderate effect. Eight of these 10 
patients had warfarin-related ICH, which has high mortality83,218 and treatment 
with PCC might not, as discussed above, improve the outcome of these patients 
240, Additionally, 2 of these 8 patients received suboptimal doses of PCC and 3 
of them did not receive vitamin K with PCC. In fact, the INR in 4 of the 8 
patients after treatment with PCC ranged between 1.4 to 1.6 suggesting a 
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rebound effect of VKA caused by the lack of vitamin K administration or the 
low PCC dose. The remaining 2 of the 10 patients with suboptimal effect of PCC 
had GI bleeding where other local factors (e.g. arterial bleeding from an ulcer or 
esophageal variceal bleeding) could have played an important role in the 
continued bleeding despite of the correction of coagulation with PCC. 
Only 57% of all patients had an INR of less than 1.5 after PCC administration in 
our study. Several factors might have contributed to this relatively low 
proportion of INR correction. First, there was in several instances limited local 
supply of PCC resulting in some of the patients receiving lower doses than 
recommended by us. Second, in patients with emergency - although minor - 
surgical intervention, the INR was sometimes reversed intentionally to only 1.6-
1.8 depending on the type of surgery performed. However, the clinical 
assessment showed good effect of PCC treatment in 94% of all patients. This 
begs the question whether the weight- and INR-based dosing of PCC leads to 
overtreatment. In a recent study a low, fixed dose of PCC seemed effective to 
manage VKA-associated bleeding241. 
 
Strength 
The main strength in this study is the prospective multicenter design with an 
initial formal sample size calculation according to the rule of three242. The cohort 
in our study represents one of the largest published with PCC treated patient.  
Additionally, we used both a clinical end point of efficacy and a laboratory 
endpoint (INR) for the overall assessment of the treatment efficacy. We relied on 
two independent investigators to add to the objectivity of efficacy assessment. 
We included both patients who needed reversal with PCC because of a serious 
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VKA-related bleeding and those on VKA requiring emergency surgery. For the 
safety endpoint, we focused on thromboembolic events occurring up to 7 days 
after PCC administration, as shorter or longer follow-up would mean that we 
either missed cases that were related to PCC or included events that were highly 
unlikely to be caused by PCC. 
 
 Limitations 
The main limitation is that we failed to include all cases treated with PCC from 
the different centers consecutively. However, this occurred randomly rather than 
systematically and should not affect the validity of the study. Another limitation 
is that we did not have a control arm to enable us to assess the PCC-attributable 
increased risk of thromboembolism. Such a design is hardly feasible and has 
many ethical issues since PCC is regarded as the first line of reversal for VKA in 
the event of a serious bleeding or emergency surgery in Sweden. 
 
Comparison with other studies 
Four previously published studies, including 100 patients each, reported 
thromboembolism rates after PCC treatment of 0-2%243-246, which is comparable 
to the results of our study when taking into consideration the confidence interval 
(3.8%, [95% CI, 1.4-8.0%]).  The incidence of stroke in patients with cardiac 
indication for VKA or previous stroke (2.5%) is comparable to that reported in 
two studies on bridging with LMWH peri-operatively after withholding VKA 
without active reversal227,228,242, supporting the minimal-if any- PCC-attributable 
risk increase for thromboembolism. Most of the events seen in our study were 
arterial, which is consistent with the findings in another study226. 
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The mortality rate within one week after VKA reversal with PCC in our study 
(6.3%) is comparable to the 7% in another published cohort247. Much higher 
mortality rates (28%) have been reported in an other study on the reversal of 
VKA with PCC248, which could be explained by difference in the characteristics 
of patients included, such as the higher prevalence (62%) of patients with ICH in 
the latter study and a different follow-up period. 
Study IV: Management and Outcomes of Major Bleeding During 
Treatment With Dabigatran or Warfarin 
 
Main findings 
We are here presenting data from the largest cohort of patients with dabigatran-
related major bleeding, and who are on anticoagulation either for SPAF or for 
VTE. We reported a number of important results. First the patients who suffered 
a major bleeding on dabigatran were significantly older, had more severe renal 
impairment, and more frequent concomitant use of antiplatelet agents and 
NSAIDs. This indicates that patients who suffered a major bleeding on 
dabigatran were higher risk patients, where other factors than only dabigatran 
itself could have contributed to the bleeding. This brings up the possibility of 
lowering the bleeding risk by supporting the use of a lower dabigatran dose, as 
suggested by other guidelines116, or by avoiding concomitant use of antiplatelet 
agents or NSAIDs. With respect to the management of major bleeding in the 
phase III trials, almost all of the dabigatran related bleeding events were 
managed by supportive care and transfusion of blood and blood products 
whereas very few patients received coagulation factor concentrates. There was 
more frequent use of red cell transfusions in the dabigatran than in the warfarin 
group, which can be explained by the higher incidence of GI bleeding in the 
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dabigatran arm. Furthermore, a larger proportion of GI bleeds was transfused 
with red cells among the dabigatran-treated patients than the warfarin-treated 
patients (71% versus 54% transfused, respectively). This was balanced by the 
more frequent use of plasma in the warfarin arm, which probably reflects the 
effort to reverse the anticoagulant effect of this drug. 
The higher incidence of GI bleeding in the dabigatran arm together with the 
lower incidence of ICH might also explain the greater reduction in the 
hemoglobin level from the baseline level at the time of randomization to the time 
of admission for the bleeding event. A possible higher incidence of occult GI 
bleeding in the dabigatran arm might also explain the reduction of hemoglobin 
seen in patients who had no major bleeding event. The drop was very modest 
(1.1 g/L per 12 months for the dabigatran 150 mg group), which is reassuring. 
The most important finding in our study is, that despite the unavailability of a 
specific reversal agent for dabigatran in case of a major bleeding, the outcome of 
patients who suffered this on dabigatran was better than when on warfarin, as 
evident by the significantly shorter period of stay in the intensive care unit, and 
the trend to lower 30-day all-cause mortality in the dabigatran arm, which 
becomes statistically significant when patients in the AF trial (RE-LY) are 
analyzed separately.  
 
Strength 
The main strength of the study is the large sample size, where we included 
information on consecutive bleeding events, collected both from databases and 
from serious adverse events- and major bleeding narratives from all the 5 long-
term treatment phase III trials. Even though the data was collected through 
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retrospective review of the charts, the information was originally recorded 
prospectively in the specific CRFs of the phase III trials, The inclusion of only 
centrally adjudicated major bleeding events adds to the strength of the study, and 
it is such bleeds that have the greatest impact on the general health system and 
on individual patient management. We analyzed events on-treatment or up to 3 
days after the last study drug dose to ensure that the bleeding was related to the 
drug itself. The data were reviewed by 2 independent investigators, and then 
validated against the central databases to ensure the validity and completeness of 
information. Finally, the use of quantitative and hard end points, like length of 
stay in the intensive care unit and mortality, adds to the strength of the study. 
 
Limitations 
There are a number of limitations in this study. First, the source population was 
derived from 5 phase III trials where patients were enrolled using strict inclusion 
and exclusion criteria and followed according to a rigorous pre-specified 
protocol, which differs from the real world. Therefore resources and outcomes in 
clinical practice might differ from the results presented in our study. It should be 
recognized that patients treated with dabigatran or warfarin were selected 
according to the same criteria, minimizing the influence of “selection bias” on 
the results. Second, we included all the patients with major bleeding events in the 
trials without doing a sample size and power analysis, but the large number of 
patients in the source population, where more than 16000 patients were treated 
with dabigatran (almost double the current number of patients on all the DOACs 
in Sweden) means that the clinical significance of any effect – found or not 
found in the study- would be substantial in the real world. Third, the data 
recorded in the major bleeding events and in the adverse event narratives were 
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intended for reporting the event itself and no specific protocol was used to guide 
the management of the bleeding event. The decision on how to treat the bleeding 
was at the discretion of the local investigator, and this resulted in wide variation 
of treatments given. Such differences are likely to reflect the real world picture. 
We were not able to draw any conclusion on the efficacy of coagulation factor 
concentrates in the management of dabigatran associated bleeding, because of 
the small number of patients treated with these agents. 
One issue that needs to be considered carefully is the unexpected low rate of 
anticoagulation reversal in the warfarin treated group. In our study, only a third 
of patients with warfarin-related major bleeding received any reversal, and 
almost all reversal was with plasma while only 12 received rapid reversal (10 
patients received PCC and 2 received rFVIIa). Furthermore, only 31% received 
vitamin K. This low rate of reversal apparently represents the real world 
scenario, as mentioned above, since the treatment of any major bleeding was left 
to the local physician and carried out according to local guidelines in the 
hospitals. The utilization of plasma instead of PCC can be explained by the 
inclusion of patients from several centers where plasma is the first line of 
reversal because PCC is either unavailable or too costly. Using plasma instead of 
PCC means that it takes significantly longer time for INR correction, and one 
might argue that this could influence patient’s outcome, including mortality – 
although not necessarily for ICH, as discussed in Study II.  
Finally, the RELY trial had an open design and all our data collection from the 
bleeding events was done through retrospective review, but as mentioned above, 
the information was recorded prospectively into specifically designed forms 
during the studies and neither this nor the open study design would affect the 
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hard endpoints that our conclusions are based on. 
 
Comparison with other studies  
The number of bleeding events reported in our study is lower than that of the 
combined bleeding events reported in the 5 individual phase III studies (1121 vs 
1507), this is because we only analyzed data from patients who had a major 
bleeding while on or within 3 days after the last study drug to include strictly the 
events that could be related to the study drug.  
In our study, patients suffering a major bleeding on dabigatran had lower renal 
function than those on warfarin. In an analysis of the RELY trial, both age and 
renal function were found to be risk factors for bleeding but there was no 
interaction between the renal function and study drug106, contrary to what is 
expected from a drug dependent on renal elimination like dabigatran. Yet renal 
function was an independent risk factor for bleeding on LMWHs, which are also 
dependent on renal function249. We also found that concomitant treatment with 
antiplatelet agents increased the bleeding risk on dabigatran, similar to 
previously published findings on combination of antiplatelet agents with 
warfarin or dabigatran 134,137 
In our study, we presented data on the 30-day all-cause mortality as opposed to 
another published analysis from the RE-LY trial, where fatal bleeding events, i.e. 
bleeding events that resulted in death, without specific consideration to the time 
from the last intake of study medicine, were presented106. In this study, rates of 
fatal bleeding on warfarin were not statistically different from those on 
dabigatran 150mg but significantly higher than those on dabigatran 110mg. A 
separate subgroup analysis of ICH in the RE-LY trial has also been published 
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and showed significantly lower number of fatal ICH with both dabigatran doses 
compared to warfarin 224. These two studies used different definitions and 
selected specific subgroups for their analysis and are difficult to compare with 
the results of our study. 
 
FUTURE PERSPECTIVES ON THE MANAGEMENT OF 
HEMORRHAGIC COMPLICATIONS OF ANTITHROMBOTICS 
Bleeding, especially ICH, is the most serious complication of treatment with 
anticoagulants. All the anticoagulants available on the market today have 
bleeding as a side effect, although a recent work on a factor XIIa inhibitory 
antibody in an animal model involving extracorporeal circulation showed very 
promising results with thromboprotective effect without associated increase in 
bleeding risk29. It is unlikely that this antibody will be marketed within the near 
future, and the problem of bleeding on anticoagulants will continue to be a 
challenge to manage. Vitamin K antagonists have been available since six 
decades and PCC can normalize the prolongation of INR induced by VKA but 
data on the clinical efficacy is still scarce. Several classes of DOACs are 
currently either licensed or in the final stages of clinical trials These agents have 
different bleeding risk profiles from each other and from VKA and there are no 
commercially available antidotes yet. Specifically, these new agents have been 
shown to be associated with significantly lower rates of ICH. It is very intriguing 
to see if findings of Study I apply to DOACs and a study with a similar design 
but including patients on the different DOACs would be the next logical step.  
Another question of interest would be to see if there is any subgroup of patients 
with ICeH who would benefit significantly from treatment with PCC as 
compared to plasma. In our study the median time to administration of PCC was 
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4 hours, and the question is how the results would be if we managed to give 
patients PCC much earlier after the onset of symptoms. Today, patients on 
warfarin are excluded from the stroke-thrombolysis protocols if they have an 
INR ≥1.7. It is, however, interesting to establish a broader “stroke” protocol that 
ensures rapid care and radiological investigation of all patients with new 
neurological symptoms, where the finding of ICH and elevated INR would lead 
to quick administration of PCC. In such settings, comparison of PCC 
administered shortly after symptoms with either plasma or historical data might 
give further insights in the utility of PCC. 
One study has shown that PCC is safe and efficacious in the reversal of 
rivaroxaban196. A consequence of Study III would be a large-scale prospective 
study that evaluated the safety and efficacy of PCC in the reversal of several 
DOACs, especially the Xa inhibitors. Parallel with that, it would also be 
interesting to see if managing the major bleeding events on the Xa inhibitors by 
supporting the patients hemodynamically without the administration of a specific 
reversal agent leads to comparable results to those seen in Study IV. The large 
registries available in Sweden, including the Swedish Prescribed Drug Register 
and the Inpatient Register, allow for unique research possibilities with the high 
quality data collected in these registers, and allow for answering complicated 
questions with relatively limited resources. This is an area that should be 
explored further.  
It also of importance that our studies, especially Study I, II and IV, present data 
that were not previously available in other publications, but additional studies are 
needed to confirm our findings.  
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5 CONCLUSIONS 
 
• In patients suffering ICH while on warfarin treatment, the optimal timing for 
resumption of warfarin seems to be, contrary to previous studies and 
recommendations, between weeks 10 and 30 after the bleeding. This 20-
week span allows for individual risk benefit assessment of recurrent ICH 
versus thromboembolism to select the suitable point of resumption. 
• Treatment with PCC for patients with VKA-associated ICeH, even though 
resulting in a more rapid correction of INR, does not seem to reduce the 30-
day all-cause mortality. 
• Patients treated with PCC to reverse warfarin in case of serious bleeding or 
before emergency surgery are at an increased risk of developing 
thromboembolic events, mainly arterial. Several factors might contribute to 
this increased risk including patient characteristics such as a pre-existing 
thrombogenic process, for which the patient is anticoagulated, and activation 
of coagulation by the bleeding or surgery. The contribution of PCC to this 
increased risk seems to be minimal if any.  
• Patients who suffer a major bleeding event on dabigatran are older, have 
worse renal function and are more frequent concomitant use of antiplatelet 
agents or NSAID than those who develop major bleeding on warfarin. This 
indicates that dabigatran may be associated with a higher bleeding threshold 
than that of warfarin. 
• Even in the absence of a specific reversal agent for dabigatran, the outcome 
of patients with major bleeding on dabigatran treated with supportive 
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measure seems to be better than those on warfarin, as evident by a shorter 
stay in the intensive care unit and lower 30-day all-cause mortality in the 
dabigatran arm.  
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